

**DECLARATION FORM ON NOTHING TO DECLARE OR NOTHING NEW TO DECLARE FOR
USE IN THE INFORMATION EXCHANGE**

Measure	Nothing to declare	Nothing new to declare
A, part 1	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (i)	<input type="checkbox"/>	<input checked="" type="checkbox"/>
A, part 2 (ii)	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (iii)	<input type="checkbox"/>	<input type="checkbox"/>
B (i)	<input type="checkbox"/>	<input type="checkbox"/>
B (ii)	<input type="checkbox"/>	<input type="checkbox"/>
C	<input type="checkbox"/>	<input type="checkbox"/>
D	<input type="checkbox"/>	<input type="checkbox"/>
E	<input type="checkbox"/>	<input checked="" type="checkbox"/>
F	<input type="checkbox"/>	<input checked="" type="checkbox"/>
G	<input type="checkbox"/>	<input type="checkbox"/>

(Please mark the appropriate box(es) for each measure, with a tick.)

Date: 29 May 2007

State Party to the Convention: Australia

Exchange of data on research centres and laboratories¹

Australia's submission regarding questions 1-7 of Form A, part 1 is at **Attachment 1.1 to 1.4**, below.

1. Name(s) of facility² _____
2. Responsible public or private organization or company _____

3. Location and postal address _____

4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

5. Number of maximum containment units³ within the research centre and/or laboratory, with an indication of their respective size (m²)

6. If no maximum containment unit, indicate highest level of protection

7. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate

¹The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.
²For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark "Declared in accordance with Form A, part 2 (iii)".
³In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent

Exchange of data on research centres and laboratories***Background Information***

Australia has three maximum containment units which meet the criteria for a “maximum containment laboratory” as specified in the 1983 WHO Laboratory Biosafety Manual.

They are:

- The Australian Animal Health Laboratory (**Attachment 1.2**)
- The National High Security Quarantine Laboratory (**Attachment 1.3**)
- The Queensland Health Scientific Services Virology Laboratory (**Attachment 1.4**)

Data on these facilities relating to questions 1 to 7 of Form A, Part 1 are provided below in accordance with the Annex to the Final Declaration on Confidence Building Measures.

The National High Security Laboratory (NHSQL) operates under the auspices of the Victorian Infectious Diseases Reference Laboratory (VIDRL) in Melbourne. Additional maximum containment laboratory facilities are being established at VIDRL that will boost capability for responding to a terrorist attack involving bioagents. In addition, some Australian hospitals and university departments have lower level containment units where diagnostic and research work is conducted.

During April 2006, Australian Government agencies hosted briefing sessions for laboratory stakeholders on laboratory biosecurity. The briefing sessions were intended to raise awareness of issues surrounding security for laboratories handling high-risk pathogens and to facilitate communication between stakeholders and government on regulatory models that are being proposed to address gaps in Australia's current regulation on the storage, sale and handling of hazardous biological material. Two reports were provided: the ‘Laboratories Risk Context Statement’, which was developed following an Australian Security Intelligence Organisation (ASIO) sectoral threat assessment on Australian laboratories holding high-risk human pathogens. The Risk Context Statement is intended to be used by individual laboratory owners and operators to assist in identification of local risks taking into account of operational and environmental circumstances. In addition, the draft report of the ‘Council of Australian Governments’ (COAG) Review of Hazardous Biological Materials’ which provided recommendations for regulation to address the security of biological agents that could be used as bioterrorist weapons against humans, animals and plants was provided for industry consultation prior to formal adoption of the recommendations.

The CSL facility declared in previous years does not meet PC4 requirements.

Exchange of data on research centres and laboratories**1. Name of facility**

Australian Animal Health Laboratory

2. Responsible public or private organisation/ company

Commonwealth Scientific and Industrial Research Organisation (Federal Government) and the Department of Agriculture, Fisheries and Forestry (Federal Government). Note: Australia has a two-tiered system of Government, with the Federal Government and, to a lesser extent, the six respective State Governments and two Territories all involved in the formulation and implementation of Government policy.

3. Location and postal address

Location	Postal address
5 Port Arlington Road Geelong, Victoria AUSTRALIA	PO Bag 24 Geelong VIC 3220 AUSTRALIA

4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

This facility receives no funding from the Australian Government Department of Defence. The AAHL is funded by the Australian Government, via CSIRO and the Department of Agriculture, Fisheries and Forestry. It is also funded by industry organisations and commercial companies.

5. Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m²)

One maximum containment system and enclosure. Total floor space 11,000m², comprising three main parts: a large-animal accommodation area, total floor area about 3,500 m² made up of 29 rooms – each of these with a floor area of about 24 m² – and with a service area, incinerator, and autopsy area.

A laboratory complex of total floor area about 3,500 m² made up of three functional laboratory suites – each of these with a floor area of about 1,100 m² – and each comprised of six laboratories and four attached small-animal rooms. The laboratory suites are for diagnosis, pathology and virology. There are attached service areas.

A common support area for glass washing, tissue culture, laundry and other services.

6. If no maximum containment unit, indicate highest level of protection

N/A

Exchange of data on research centres and laboratories

7. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate.

The AAHL plays a vital role in maintaining Australia's capability to quickly diagnose exotic (foreign) and emerging animal diseases. This is achieved through ongoing research programs to develop the most sensitive, accurate and timely diagnostic tests, which are critical to the success of any eradication campaign in the event of a disease outbreak.

AAHL also undertakes research to develop new diagnostic tests, vaccines and treatments for endemic animal diseases of national importance. Major diseases of livestock, aquaculture animals, and wildlife, are studied. AAHL includes a high-biocontainment facility, to safely fulfil its major role of diagnosing emergency animal disease outbreaks.

The laboratory is a World Animal Health Organisation reference laboratory for avian influenza, Newcastle disease, bluetongue disease, and epizootic haematopoietic necrosis virus (EHNV). The AAHL is also an OIE Collaborating Centre for New and Emerging Diseases, a WHO Collaborating Centre for Severe Acute Respiratory Syndrome (SARS), and a national reference laboratory for rabies and brucella.

Exchange of data on research centres and laboratories**1. Name of facility**

National High Security Quarantine Laboratory (NHSQL)

2. Responsible public or private organisation/company:

Department of Health and Ageing (Commonwealth Government), Department of Human Services (State government).

3. Location and postal address:

Location	Postal address
Victorian Infectious Diseases Reference Laboratory 10 Wreckyn Street North Melbourne Victoria AUSTRALIA	National High Security Quarantine Laboratory c/o VIDRL Locked Bag 815 Carlton South VIC 3053 AUSTRALIA

4. Source(s) of financing, of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

This facility receives no funding from the Australian Government Department of Defence. It receives funding from Commonwealth and State Departments of Health.

5. Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m²)

One high security laboratory, containing two portable isolation units. Total area 90m².

6. If no maximum containment unit, indicate highest level of protection

N/A

7. Scope and general description of activities, including type(s) of micro-organism and/or toxins as appropriate

The diagnosis of possible imported cases of viral haemorrhagic fever or other quarantinable viral diseases such as yellow fever. Development of laboratory tests and protocols for exotic respiratory viral diseases, including influenza A/H5N1 ('bird flu') and SARS. In addition, VIDRL has established and maintained the capability to perform diagnostic testing for the variola virus. See also, background information at Attachment 1.1.

Exchange of data on research centres and laboratories**1. Name of facility**

Queensland Health Scientific Services.

2. Responsible public or private organisation/company:

Queensland Department of Health (State Government).

3. Location and postal address:

Location	Postal address
39 Kessels Road Coopers Plains Queensland AUSTRALIA	PO Box 594 Archerfield QLD 4108 AUSTRALIA

4. Source(s) of financing, of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

This facility receives no funding from the Australian Government Department of Defence. It receives funding from Commonwealth and State Departments of Health.

5. Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m2)

Two. Total area 150m2.

If no maximum containment unit, indicate highest level of protection

N/A.

7. Scope and general description of activities, including type(s) of micro-organism and/or toxins as appropriate

The maximum containment facilities service a state government public health virology laboratory which has both a diagnostic and a research function. The laboratory is a WHO Centre for Arbovirus Reference and Research. The maximum containment facilities are used for the development and performance of diagnostic tests on patients with suspected exotic or endemic viral illness requiring such containment facilities, such as Hendra virus or exotic haemorrhagic fever viruses. The laboratory currently has no other PC4 pathogens but has introduced the SARS coronavirus into this facility for diagnostic purposes. The laboratory intends to introduce reagents useful for the diagnosis of a number of exotic viral diseases including Ebola, Lassa, Junin, Rift Valley fevers and Hantavirus among others. These reagents will consist of either inactivated diagnostic reagents, cloned viral subunits or live virus.

In 2006 no research was performed in the QHSS PC4 laboratory.

CONFIDENCE BUILDING MEASURE A (Part 2(i))

[Form A, part 2(i)]

National biological defence research and development programme Declaration

Is there a national programme to conduct biological defence research and development within the territory of the State Party, under its jurisdiction or control anywhere? Activities of such a programme would include prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

Yes. Australia has a science and technology program in defence against biological agents, which occurs in the Defence Science and Technology Organisation (DSTO), Department of Defence, as detailed below (see Form A, Part 2(ii)).

If the answer is Yes, complete Form A, part 2 (ii) which will provide a description of the programme.

National biological defence research and development programme**Description**

1. State the objectives and funding of the programme and summarize the principal research and development activities conducted in the programme. Areas to be addressed shall include: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

The objective of the program is to provide the Australian Government with an appropriate understanding of the issues pertinent to protection against biological weapons. The program also assists in the provision of a defensive capability for the Australian Defence Force (ADF) and contributes to Defence support to the civil power in the management of biological threats to the community. The program enhances the ability of the ADF to operate in parts of the world where biological weapons might be used. It also enhances Australia's ability to contribute to biological arms control verification. The principal research activities are concerned with the detection and analysis of biological species that have been identified as potential biological warfare agents and development of medical countermeasures to those agents. The program also covers toxins that are considered threats in terms of both the Biological and Chemical Weapons Conventions.

2. State the total funding for the programme and its source.

The program is funded solely by the Australian Department of Defence, with an allocation for the current financial year (July 2006-June 2007) of approximately \$2 385 000.

3. Are aspects of this programme conducted under contract with industry, academic institutions, or in other non-defence facilities?

Yes. Work is contracted to non-defence facilities.

4. If yes, what proportion of the total funds for the programme is expended in these contracted or other facilities?

For the Financial Year (2006-2007), the following payments were made;

- \$80 000 to James Cook University
- \$60 000 to the Cooperative Research Centre (CRC) for Diagnostics.
- \$15 000 to CSIRO Australian Animal Health Laboratories part of the Cooperative Research Centre (CRC) for Biosecurity

5. Summarize the objectives and research areas of the programme performed by contractors and in other facilities with the funds identified under paragraph 4.

The James Cook University of Technology funding is to support a post doctoral fellow to undertake investigations into the causative organism of the disease Q-Fever.

In a collaborative research project, DSTO and CSIRO are examining the neutralizing capacity of mesophase nanomaterials to bind the plant toxin ricin.

The program includes an association with the CRC - Diagnostics that aims to produce high affinity reagents that can be used in the treatment or detection of biological agents. This interaction is through the funding of two PhD students, one located at the Commonwealth Scientific and Industrial Research Organisation (CSIRO) - Health Science and Nutrition, Parkville, Victoria, and the other at LaTrobe, University, Bundoora, Victoria.

The funding to CSIRO Australian Animal Health Laboratories supports a DSTO employee undertaking doctoral studies in developing detection methods for uncharacterised viruses.

6. Provide a diagram of the organizational structure of the programme and the reporting relationships (include individual facilities participating in the programme).

The organisational structure is as follows. There is a single active research cell operating within the Department of Defence within the hierarchy represented below.



7. Provide a declaration in accordance with Form A, part 2 (iii) for each facility, both governmental and non-governmental, which has a substantial proportion of its resources devoted to the national biological defence research and development programme, within the territory of the reporting State, or under its jurisdiction or control anywhere.

See Form A, Part 2(iii) and the associated attachment (**Attachment 2**) for Australia’s response.

National biological defence research and development programme

Facilities

Complete a form for each facility declared in accordance with paragraph 7 in Form A, part 2 (ii).

Australia’s submission of Form A, Part 2 (iii) is at **Attachment 2**.

In shared facilities, provide the following information for the biological defence research and development portion only.

1. What is the name of the facility?
2. Where is it located (include both address and geographical location)?
3. Floor area of laboratory areas by containment level:
 - BL2 _____ (sqM)
 - BL3 _____ (sqM)
 - BL4 _____ (sqM)
 - Total laboratory floor area _____ (sqM)
4. The organizational structure of each facility.
 - (I) Total number of personnel _____
 - (ii) Division of personnel:
 - Military _____
 - Civilian _____
 - (iii) Division of personnel by category:
 - Scientists _____
 - Engineers _____
 - Technicians _____
 - Administration and support staff _____
 - (iv) List the scientific disciplines represented in the scientific/ engineering staff.
 - (v) Are contractor staff working in the facility? If so, provide an approximate number.

(vi) What is (are) the source(s) of funding for the work conducted in the facility, including indication if activity is wholly or partly financed by the Ministry of Defence?

(vii) What are the funding levels for the following programme areas:

Research

Development

Test and evaluation

(viii) Briefly describe the publication policy of the facility:

(ix) Provide a list of publicly-available papers and reports resulting from the work during the previous 12 months. (To include authors, titles and full references.)

5. Briefly describe the biological defence work carried out at the facility, including type(s) of micro-organisms* and/or toxins studied, as well as outdoor studies of biological aerosols.

*Including viruses and prions.

National biological defence research and development programme**Facilities**

Australia has one facility that meets the criteria of paragraph 7 in Form A, part 2 (ii).

1. Name

Human Protection and Performance Division, DSTO

2. Location

Location	Postal address
506 Lorimer Street Fishermans Bend Victoria AUSTRALIA	Platforms Sciences Laboratory (PSL) 506 Lorimer Street Fishermans Bend Victoria AUSTRALIA

3. Floor Area	BL2	150 square metres
	BL3	60
	BL4	nil

4. Personnel

- (i) Total of 25 staff years effort for the combined biological defence and arms control programs, with contributions from 33 personnel.
- (ii) All are civilian.
- (iii) 32 scientists, 1 technician, nil engineers, shared administrative and support staff.
- (iv) Biochemistry, molecular biology, microbiology, immunology, chemistry, pharmacology, physicists.
- (v) Yes—there are two PhD students working as contractors on this program at the facility.
- (vi) Currently wholly financed by the Department of Defence, there is expected to be other funding in the 2006-2007 financial year from the Department of Health and Aging, Emergency Management Australia and Australia Post, amounts are as yet unknown.
- (vii) Research funded at ca. \$2 385 000 per annum.
- (viii) Publication in scientific journals is encouraged, and staff are expected to maintain their professional status by such publication.
- (ix) The publications are listed at **Attachment 4** (see Form C).

5. Description of Biological Defence Work

Various types of work are undertaken, as outlined in the following sections:

(1) Detection of biological entities recognised as potential biological warfare agents

Immunological and gene based techniques for rapid identification of BW agents are being investigated.

Recombinant and colostrum derived antibodies, and combinatorial peptides are being produced to a number of BW agents, including *B. pseudomallei*, *Bacillus anthracis*, anthrax toxins and ricin. Platforms for the amplification of antibody avidity, such as self-assembling gels, are also being investigated. Binding inhibition and cytotoxicity assays are being developed to assess the usefulness of potential therapeutic agents such as antibodies, peptides and aptamers.

PCR assays for the rapid detection of potential BW agents. Current research focuses on the evaluation of diagnostic tools that enable rapid detection of microbial antibiotic resistance and genetically manipulated bacteria.

(2) Physical methods for rapid detection of bio-aerosols

Methods of particle characterisation for provision of rapid warning of a bio-aerosol are being assessed.

(3) Treatment/Toxicology

Cultured human lung cells are being developed as a test bed for examining potential therapeutic compounds against toxin agents. Compounds for treatment of ricin intoxication are currently being examined.

A program for the development of DNA vaccines against selected agents is being pursued.

(4) Detection of biological toxins using physico-chemical methods

Studies on detection of biological material using mass spectrometry and other physico-chemical methods are being conducted to determine their utility for field detection of biological toxins and BWC verification procedures. This work has included the analysis of ricin and crude extracts of ricin by MALDI and FT-ICR mass spectrometry.

(5) Strengthening the Biological Weapons Convention (BWC)

A BWC Regional Workshop, co-hosted by Australia and Indonesia, was convened to help BWC States Parties in South East Asia become better engaged with the Geneva-based three-year program of work as a means to reduce the possibility of bioterrorism in the region, or the inadvertent assistance by states in the region to biological weapons programs being developed elsewhere.

**Background information on outbreaks of reportable
infectious diseases**

In 2006, Australia had no outbreaks of infectious diseases and similar occurrences caused by toxins that deviate from the normal pattern. For this reason, we report the information requested in Form B(i) with respect to diseases of humans (see **Attachment 3.1**), animals (see **Attachment 3.2**) and plants (see **Attachment 3.3**), but make no formal report regarding the information requested in Form B(ii). We provide, however, information relevant to Form B(ii) regarding animal plant diseases in Attachments 3.2 and 3.3, respectively.

Background information on outbreaks of reportable infectious diseases

In accordance with the requirements agreed at the Third Review Conference, a summary table of notifiable diseases for Australia for the years 1999 to 2006 is attached as Form B (i).

(A) Human diseases

The Australian Government Department of Health and Ageing has overall responsibility for national disease surveillance. The Department's Office of Health Protection routinely receives diagnostic data from key medical laboratories throughout Australia.

Each Australian State and Territory has legislation which requires doctors, hospitals and/or laboratories to report the occurrence of certain diseases, known as "notifiable diseases". Under the auspices of the Communicable Diseases Network of Australia (the Network), the State and Territory health authorities provide data on an agreed set of notifiable diseases to the Australian Government Department of Health and Ageing. The data are collated by the Department and published quarterly in the *Communicable Diseases Intelligence* and updated three times per week on the Department's website (www.health.gov.au/cda). *Communicable Diseases Intelligence* is sent to the World Health Organization and to approximately 1,100 health professionals and researchers both nationally and internationally as well as published on the Department website.

The Network meets fortnightly by teleconference. It provides a forum for information exchange on communicable disease activity in Australia and New Zealand and enables Federal and State health authorities to cooperate in taking prompt action to control outbreaks.

No. of cases of Nationally Notifiable Communicable Diseases in Humans, 1999 – 2006

Disease	1999	2000	2001	2002	2003	2004	2005	2006*
AIDS	206	261	208	225	222	160	NA	NA
HIV	714	755	765	848	861	886	NA	NA
Anthrax	NN	NN	0	0	0	0	0	1
Barmah Forest virus infection	639	646	1,145	869	1,369	1,106	1,319	2,120
Botulism	1	2	2	0	1	1	3	1
Brucellosis	54	29	20	40	20	39	41	50
Campylobacteriosis	12,377	13,683	16,549	15,106	15,357	15,584	16,468	15,399
Congenital Rubella	1	0	0	1	3	1	1	0
Congenital Syphilis	3	5	21	18	13	12	15	14
Chancroid	1	0	0	NN	NN	NN	NN	NN
Chlamydial infection	14,090	16,989	20,623	24,507	30,436	36,222	41,311	47,074
Cholera	3	2	4	5	1	5	3	3
Cryptosporidiosis	841	1,152	1,639	3,301	1,224	1,684	3,209	3,200

Attachment 3.1 *continued*

CONFIDENCE BUILDING MEASURE B(i)

[Form B(i) continued]

Disease	1999	2000	2001	2002	2003	2004	2005	2006*
Dengue	120	198	141	168	860	351	218	187
Diphtheria	0	0	1	0	0	0	0	0
Donovanosis	17	22	32	17	16	10	13	4
Flavivirus NEC	62	67	89	72	60	61	29	33
Gonococcal infection	5,603	5,899	6,311	6,296	6,793	7,193	8,015	8,568
Haemolytic uraemic syndrome	22	17	3	12	15	16	20	13
Haemophilus influenzae type b	41	27	20	30	19	15	17	22
Hepatitis (NEC)		1	3				0	2
Hepatitis A	1,558	817	553	392	431	319	325	280
Hepatitis B (incident)	309	414	424	383	346	281	245	295
Hepatitis B (unspecified)	6,843	7,790	8,078	6,481	5,823	5,819	6,396	6,297
Hepatitis C (incident)	451	548	712	451	519	450	357	430
Hepatitis C (unspecified)	19,831	19,784	19,585	14,806	13,718	12,862	12,250	12,099
Hepatitis D	20	28	20	21	27	28	30	31
Hepatitis E	10	12	14	13	12	28	31	24
Hydatid infection	3	4	NN	NN	NN	NN	NN	NN
Influenza (laboratory confirmed)	73	105	1,308	3,671	3,483	2,133	4,567	3,139
Japanese encephalitis	1	0	0	0	1	1	0	0
Kunjin virus	2	4	5	0	18	12	1	3
Legionellosis	250	472	312	316	333	311	335	349
Leprosy	8	4	10	6	5	7	10	5
Leptospirosis	320	255	250	159	127	177	130	147
Listeriosis	63	67	65	62	69	67	54	61
Malaria	716	969	736	475	595	558	822	771
Measles	237	110	141	32	93	45	10	125
Meningococcal infection	587	628	686	687	558	405	394	320
Mumps	183	213	117	67	77	102	241	275
Murray Valley encephalitis	0	16	6	2	0	1	2	1
Ornithosis	81	102	138	199	199	236	161	167
Pertussis	4,359	5,997	9,590	5,462	5,095	8,752	11,200	11,000
Pneumococcal disease (invasive)	NN	NN	1,779	2,466	2,237	2,377	1,684	1,441
Q fever	516	574	694	762	562	463	355	400
Ross River virus infection	4,376	4,227	3,235	1,452	3,848	4,210	2,544	5,491
Rubella	371	322	265	257	54	31	31	60
Salmonellosis (NEC)	7,013	6,217	7,123	7,794	7,007	7,834	8,441	8,267
Shigellosis	533	491	573	504	443	522	732	546

Attachment 3.1 *continued***CONFIDENCE BUILDING MEASURE B(i)***[Form B(i) continued]*

Disease	1999	2000	2001	2002	2003	2004	2005	2006*
SLTEC/VTEC	52	43	46	58	51	48	87	70
Syphilis - Infectious	195	177	251	359	453	615	621	813
Syphilis - duration more than 2 years	1,499	1,602	1,135	1,084	1,204	1,578	1,582	1,864
Tetanus	2	8	3	4	4	5	2	3
Tuberculosis	1,363	1,036	940	1,037	928	1,060	1,087	1,233
Typhoid	63	57	79	69	51	76	52	77
Yersiniosis (NEC)	7	6	1	NN	NN	NN	NN	NN

NA - not available

NN - not nationally notifiable in that year

NEC - Not Elsewhere Classified

* 2006 provisional figures only

Information relevant to Measure B(ii) – no formal declaration necessary, as explained on Form B(i)

Background information on outbreaks of reportable infectious diseases

(B) Animal disease

The Australian Government Department of Agriculture, Fisheries and Forestry is responsible for national coordination on animal health matters and for providing reports on Australia's animal health status, including a joint annual return to the World Organisation for Animal Health (OIE), the Food and Agriculture Organization (FAO) and the WHO.

The following sections contain information on significant animal disease events/issues in 2006. Australia publishes quarterly reports⁴ and annual reports⁵ on animal health incidents and status, as well as providing emergency, monthly, quarterly and annual reports to the World Organisation for Animal Health (OIE)⁶. Australia's status for OIE-listed diseases for 2006 is shown in the table that follows.

⁴ <http://www.animalhealthaustralia.com.au/status/ahia.cfm>

⁵ <http://www.animalhealthaustralia.com.au/status/ahsq.cfm>

⁶ http://www.oie.int/eng/info/en_infoan.htm

Status for OIE-listed diseases

Disease	Status	Date of last occurrence/notes
Multiple-species diseases		
Anthrax	Present	Limited distribution
Aujeszky's disease	Free	Never occurred
Bluetongue	Viruses present	Restricted to specific northern areas of the country; sentinel herd program
Brucellosis (<i>Brucella abortus</i>)	Free	Australia declared freedom in 1989
Brucellosis (<i>Brucella melitensis</i>)	Free	
Brucellosis (<i>Brucella suis</i>)	Serological evidence	Occurs only in feral pigs in northern Australia
Crimean Congo haemorrhagic fever	Free	Never occurred
Echinococcosis/hydatidosis	Present	
Foot-and-mouth disease	Free	1872
Heartwater	Free	Never occurred
Japanese encephalitis	Serological evidence	Detected annually in Torres Strait and on Cape York in 1998 and 2004; not detected in Cape York sentinel program in 2005 or 2006
Leptospirosis	Present	
New World screw worm fly (<i>Cochliomyia hominivorax</i>)	Free	Never occurred
Old World screw worm fly (<i>Chrysomya bezziana</i>)	Free	Never occurred
Paratuberculosis	Present	National control/management programs
Q fever	Present	
Rabies	Free	1867
Rift Valley fever	Free	Never occurred
Rinderpest	Free	1923
Trichinellosis	Not reported	<i>Trichinella spiralis</i> not present; <i>T. pseudospiralis</i> present in wildlife
Vesicular stomatitis	Free	Never occurred
West Nile Fever	Free	Never occurred
Tularaemia	Free	Never occurred
Cattle diseases		
Bovine anaplasmosis	Present	
Bovine babesiosis	Present	
Bovine genital campylobacteriosis	Present	
Bovine spongiform encephalopathy	Free	Never occurred; National Transmissible Spongiform Encephalopathy Freedom Assurance Program includes surveillance
Bovine tuberculosis	Free	Australia declared freedom in 1997; because of the nature of the disease, sporadic residual cases may occur (the last case was in 2002)
Bovine viral diarrhoea	Present	
Contagious bovine pleuropneumonia	Free	1967; Australia declared freedom in 1973; recognised by OIE as free in 2005

Enzootic bovine leucosis	Present	Voluntary accreditation and testing programs in place; very low prevalence
Haemorrhagic septicaemia	Free	Never occurred; strains of <i>Pasteurella multocida</i> present, but not the 6b or 6e strains that cause haemorrhagic septicaemia
Infectious bovine rhinotracheitis/infectious pustular vulvovaginitis	Present	
Lumpy skin disease	Free	Never occurred
Malignant catarrhal fever	Present	
Theileriosis	Free	Nonpathogenic <i>Theileria buffeli</i> only; <i>T. parva</i> and <i>T. annulata</i> not present
Trichomonosis	Present	
Trypanosomosis (tsetse borne)	Free	Never occurred
Sheep and goat diseases		
Caprine arthritis/encephalitis	Present	
Contagious agalactia	Not reported	<i>Mycoplasma agalactiae</i> has been isolated, but Australian strains do not produce agalactia in sheep
Contagious caprine pleuropneumonia	Free	Never occurred
Enzootic abortion of ewes (ovine chlamydiosis)	Not reported	Never occurred
Maedi–visna	Free	Never occurred
Nairobi sheep disease	Free	Never occurred
Ovine epididymitis (<i>Brucella ovis</i>)	Present	Voluntary accreditation schemes in all states
Peste des petits ruminants	Free	Never occurred
Salmonellosis (<i>Salmonella Abortusovis</i>)	Free	Never occurred; <i>S. Abortusovis</i> was isolated in 1994 from two children, but surveillance has shown no evidence of infection in sheep
Sheep pox and goat pox	Free	Never occurred
Scrapie	Free	1952
Equine diseases		
African horse sickness	Free	Never occurred
Contagious equine metritis	Free	1980
Dourine	Free	Never occurred
Equine encephalomyelitis (Eastern)	Free	Never occurred
Equine encephalomyelitis (Western)	Free	Never occurred
Equine infectious anaemia	Present	Limited distribution/sporadic occurrence
Equine influenza	Free	Never occurred
Equine piroplasmiasis	Free	Last reported in 1976
Equine rhinopneumonitis	Present	
Equine viral arteritis	Serological evidence	
Glanders	Free	1891
Surra (<i>Trypanosoma evansi</i>)	Free	Never occurred
Venezuelan equine encephalomyelitis	Free	Never occurred

Swine diseases		
African swine fever	Free	Never occurred
Classical swine fever	Free	1962
Nipah virus encephalitis	Free	Never occurred
Porcine cysticercosis	Free	Never occurred
Porcine reproductive and respiratory syndrome	Free	Never occurred
Swine vesicular disease	Free	Never occurred
Transmissible gastroenteritis	Free	Never occurred
Avian diseases		
Avian chlamydiosis	Present	
Avian infectious bronchitis	Present	
Avian infectious laryngotracheitis	Present	
Avian mycoplasmosis (<i>M. gallisepticum</i>)	Present	
Avian mycoplasmosis (<i>M. synoviae</i>)	Present	
Duck virus hepatitis	Free	Never occurred
Fowl cholera	Present	
Fowl typhoid	Free	Last reported in 1952
Highly pathogenic avian influenza	Free	1997
Infectious bursal disease (Gumboro disease)	Present	Infectious bursal disease occurs in a mild form; Gumboro disease does not occur
Low pathogenic avian influenza (poultry)	Free	Never reported
Marek's disease	Present	
Newcastle disease	Viruses present	Sporadic outbreaks occur; last reported 2002
Pullorum disease	Present	
Turkey rhinotracheitis	Free	Never occurred
Lagomorph diseases		
Myxomatosis	Present	
Rabbit haemorrhagic disease	Present	Used as a biological control agent for wild rabbits
Bee diseases		
Acariosis of bees	Free	Never occurred
American foulbrood	Present	
European foulbrood	Present	
Small hive beetle	Present	Restricted distribution
Tropilaelaps	Free	Never occurred
Varroosis	Not reported	<i>Varroa jacobsoni</i> last reported in 1997 in the Torres Strait; does not occur on mainland Australia or Tasmania.
Other diseases		
Leishmaniosis	Atypical organism found	A new Leishmania species has been isolated from skin lesions in a group of captive red kangaroos. Occasionally, cases of leishmaniosis are reported in imported dogs.
Camel pox	Free	Never occurred

Table 2.2 Australia's status for other diseases of interest

Disease	Status	Date of last occurrence/notes
Listeriosis	Present	
Toxoplasmosis	Present	
Melioidosis	Present	Restricted distribution
Blackleg	Present	
Botulism	Present	
Other clostridial infections	Present	
Other pasteurelloses	Present	
Actinomycosis	Present	
Intestinal salmonella infections	Present	
Coccidiosis	Present	
Distomatosis (liver fluke)	Present	Restricted distribution
Filariosis	Present	
Mucosal disease/bovine virus diarrhoea	Present	
Vibrionic dysentery	Present	
Warble infestation	Free	Never reported
Contagious pustular dermatitis	Present	
Footrot	Present	Restricted distribution
Contagious ophthalmia	Present	
Enterotoxaemia	Present	
Caseous lymphadenitis	Present	
Sheep mange	Free	1896
Equine coital exanthema	Present	
Ulcerative lymphangitis	Free	Never reported
Strangles	Present	
Salmonellosis (<i>S. Abortus equi</i>)	Free	Never reported
Swine erysipelas	Present	
Infectious coryza	Present	
Avian encephalomyelitis	Present	
Avian spirochaetosis	Present	
Avian salmonellosis (excluding fowl typhoid and pullorum disease)	Present	
Avian leucosis	Present	

Comments on selected OIE-listed diseases

Bluetongue

Bluetongue viruses capable of causing disease are only found in parts of the far north of the Northern Territory and Western Australia. Relatively nonpathogenic strains (types 1 and 21) are

found on the east coast in Queensland and northern New South Wales. There is little overlap between the distribution of vectors of bluetongue virus and major sheep populations, because the climate conditions that favour sheep production are not conducive to the vectors.

In 2006, transmission of bluetongue viruses was observed in the endemic areas of far northern Australia and coastal New South Wales. In these areas, the prevalence was usually moderate to high. In the Northern Territory, there was widespread transmission in the northern herds; types 1 and 20 were the serotypes identified. There was no evidence of movement of the more pathogenic viruses out of the far northern 'high-risk' zone of the Northern Territory. There was limited evidence of bluetongue virus activity in sentinel herds in north of Western Australia, where serotype 1 was identified. A survey of Cape York Peninsula in Far North Queensland demonstrated circulation of serotypes 1, 21 and 23. The incidence of serotype 23 appears to be an incursion from overseas, and there was no evidence of serotype 16, which had been detected in the previous year. There was no transmission detected in central coastal Queensland, but there was evidence of a low level of infection further south than the usual limit of activity. In New South Wales, seroconversions were also detected beyond the usual southern and western limits of activity. All regions in southern Australia and most pastoral regions in eastern Australia remain free from bluetongue virus.

Anthrax

Anthrax is a notifiable animal disease subject to compulsory government controls including quarantine, disposal of carcasses, and vaccination. It is present in well-defined areas in the northern and northeastern districts of Victoria and central New South Wales. In these areas, anthrax has a low prevalence, and occurs only sporadically. Occasional outbreaks have occurred in other States. South Australia last recorded an outbreak in 1914, and Tasmania in 1933. Anthrax was diagnosed in Queensland in 1993 and 2002, and in Western Australia in 1995. The disease has never been reported in the Northern Territory. During 2006, there were 8 confirmed incidents of anthrax in New South Wales.

Information relevant to Measure B(ii) – no formal declaration necessary, as explained on Form B(i)

Background information on outbreaks of reportable infectious diseases

(C) Plant diseases

The Australian Government Department of Agriculture, Fisheries and Forestry, through the Office of the Chief Plant Protection Officer, is the peak organisation that gathers information on pests of plants. The Department is notified of exotic incursions through State Government agricultural, forestry and natural resource agencies. It also provides national leadership in responding to incursions of exotic pests and diseases of plants.

New plant pests and diseases recorded in Australia for 2006

Common Name	Scientific Name	Pest Type	Detected
Brown Spot	<i>Alternaria alternata</i> pv <i>citri</i>	Fungi	VIC, QLD
Black Canker	<i>Glomerella miyabeana</i>	Fungi	NSW, ACT
Sugarcane smut	<i>Ustilago scitaminea</i>	Fungi	QLD
Teak Rust	<i>Olivea tectonae</i>	Fungi	NT, QLD, WA
Downy mildew	<i>Plasmopara obducens</i>	Fungi	VIC
Hawaiian Leaf Spot	<i>Mycosphaerella scaevolae</i>	Fungi	NT
N/A	<i>Phytophthora fallax</i>	Fungi	VIC
Giant Land Snail	<i>Placostylus souvillei</i>	Invertebrate	QLD
Electric Ant	<i>Wasmannia auropunctata</i>	Invertebrate	QLD
Mango leaf gall midge	<i>Procontarinia matteiana</i> (suspected)	Invertebrate	QLD
N/A	Potato Spindle Tuber Viroid	Viroid	WA
N/A	Tomato Yellow Leaf Curl bigeminivirus	Virus	QLD
N/A	<i>Yucca bacilliform</i> badnavirus	Virus	VIC
N/A	Sweet Potato Virus 2	Virus	WA
N/A	Broad Bean Stain Virus Comovirus	Virus	SA
N/A	Canna Yellow Mottle Badnavirus	Virus	QLD

Information on outbreaks of infectious diseases and similar occurrences, that seem to deviate from the normal pattern

As noted on Form B(i), Australia had no outbreaks of infectious diseases and similar occurrences caused by toxins that deviate from the normal pattern. However, Attachments 3.1 and 3.2 of Form B(i) provide information relevant to that requested below.

1. Time of cognizance of the outbreak
2. Location and approximate area affected
3. Type of disease/intoxication
4. Suspected source of disease/
intoxication
5. Possible causative agent(s)
6. Main characteristics of systems
7. Detailed symptoms, when applicable
 - respiratory
 - circulatory
 - neurological/behavioural
 - intestinal
 - dermatological
 - nephrological
 - other
8. Deviation(s) from the normal pattern as regards
 - type
 - development
 - place of occurrence
 - time of occurrence
 - symptoms
 - virulence pattern

- drug resistance pattern
 - agent(s) difficult to diagnose
 - presence of unusual vectors
 - other
9. Approximate number of primary cases
10. Approximate number of total cases
11. Number of deaths
12. Development of the outbreak
13. Measures taken

Encouragement of publication of results and promotion of use of knowledge

At the Third Review Conference it was agreed that States parties continue to implement the following:

"Encouragement of publication of results of biological research directly related to the Convention, in scientific journals generally available to States parties, as well as promotion of use for permitted purposes of knowledge gained in this research."

Australia's submission of Confidence Building Measure C is at **Attachments 4.1 and 4.2**. Information relating to "Modality 2", below, is provided with respect to (A) The Australian Animal Health Laboratory (see Attachment 4.1), and (B) Defence Science and Technology Organisation (see Attachment 4.2).

In 2006 the Australian Government released a set of papers that considered the issues, and possible policy options, regarding the 'dual use' nature of the biological sciences, including the publication of research. This output is the product of an Australian Government (Department of the Prime Minister and Cabinet) funded study which included a workshop held in the previous year, which involved ethicists, scientists, and government policy advisors with an interest in countering the threat posed by biological weapons. The final report of this study provides a range of management options that could be considered by Australian Government policy makers.

Modalities

The Third Review Conference agreed on the following:

1. It is recommended that basic research in biosciences, and particularly that directly related to the Convention should generally be unclassified and that applied research to the extent possible, without infringing on national and commercial interests, should also be unclassified.
2. States parties are encouraged to provide information on their policy as regards publication of results of biological research, indicating, *inter alia*, their policies as regards publication of results of research carried out in research centres and laboratories subject to exchange of information under item A and publication of research on outbreaks of diseases covered by item B, and to provide information on relevant scientific journals and other relevant scientific publications generally available to States parties.
3. The Third Review Conference discussed the question of cooperation and assistance as regards the safe handling of biological material covered by the Convention. It concluded

that other international forums were engaged in this field and expressed its support for efforts aimed at enhancing such cooperation.

Encouragement of publication of results and promotion of use of knowledge**(A) The Australian Animal Health Laboratory (AAHL)**

AAHL's policy is to encourage the publication of research results. The following were published by staff at AAHL during 2006.

Book Chapters

Dale, C. J., Ramshaw, I. A., Ranasinghe, C., Thomson, S., De Rose, R., Pamungkas, J., Boyle, D. B. & Kent, S. J. 2006, 'Prime boost strategies in DNA vaccines', *DNA vaccines: methods and protocols*, Humana Press, Totowa, New Jersey, USA

Daniels, PW 2006, Bluetongue. In: *Annual reports of OIE reference laboratories and collaborating centres*, OIE, Paris, France, pp. 18-20.

Daniels, PW 2006, Hendra and Nipah virus diseases. In: *Annual reports of OIE reference laboratories and collaborating centres*, OIE, Paris, France, pp. 342-345.

Hyatt, AD & Whittington, RJ 2006, Epizootic haematopoietic necrosis. In: *Annual reports of OIE reference laboratories and collaborating centres*, OIE, Paris, France, pp. 454-456.

Jeggo, MH 2006, New and Emerging Diseases. In: *Annual Reports of OIE Reference Laboratories and Collaborating Centres 2004*, OIE, Paris, France, pp. 580-590.

Selleck, PW 2006, Highly pathogenic Avian Influenza. In: *Annual reports of OIE reference laboratories and collaborating centres*, OIE, Paris, France, pp. 365-369.

Thomas, JD, Jenkins, JA, Lowenthal, JW & Bean, ADG 2006, Livestock immunology: the chicken as a non-mammalian vertebrate model. In: *Encyclopedia of Life Support Systems*, UNESCO, Paris,

Yu, M., Stevens, V., Cramer, G. S. & Wang, L. F. 2006, 'One-step competition ELISA tests for the detection of antibodies to SARS in coronaviruses in different animal species', *One-step competition ELISA tests for the detection of antibodies to SARS in coronaviruses in different animal species*, Australian Animal Health Laboratory, Geelong, Vic.

Books and Reports

Cook, RW, Richards, RB and Hooper, PT 2006, *Transmissible Spongiform Encephalopathies*, ANZSDP, Canberra,

Mani, P, Langevin, P, Abraham, G, Le Blanc Smith, P et al. 2006, *Veterinary containment facilities: design and construction handbook*, International Veterinary Biosafety Working Group, Bremgarten, Switzerland,

Philpott, HG. 2006, *Hendra, Nipah, Menangle and Tioman viruses resource list*, CSIRO Information Management and Technology, Geelong, Vic,

Conference Proceedings

Abraham, G. 2006, 'Managing infected farm animals in microbiological containment', in *2nd International forum on laboratory animal science and technology*, Beijing Juhua SPA & Resort, Beijing, China, The Forum, Beijing, China,

Amos-Ritchie, R. N., Jack, P., and Boyle, D. B. 2006, 'Pathogen detection and characterization by microarrays', in *AAHL Science Day*, CSIRO AAHL, Australian Animal health Laboratory, Geelong, Vic.,

Babiuk, S. L., Bowden, T. R., Embury-Hyatt, C., Manning, L., Parkyn, G. R., Boyle, D. B., Kitching, R. P., and Copps, J. S. 2006, 'Gross pathology, histology, immunohistochemistry and clinical signs following sheep pox infection.', in *Poxvirus Iridovirus Meeting*, Indian Wells, California, USA, The Meeting, Indian Wells, California, USA,

Barnet, J. L., Cronin, G. M., Tauson, R., Downing, J. A., Janardhana, V., Lowenthal, J. W., and Butler, K. L. 2006, 'The effects of items of furniture in furnished cages on hen welfare', in *18th Australian Poultry Science Symposium*, Sydney, NSW., Poultry Research Foundation, Sydney, NSW,

Bingham, J. 2006, 'West Nile Virus and little ravens', in *Australian Biosecurity CRC/Department of Health and Ageing Arbovirus Forum*, Canberra, The forum, Canberra,

Bingham, J., Middleton, D. J., Lunt, R. A., and Green, D. 2006, 'Experimental West Nile Virus (New York 1999 strain) disease in an Australian Corvid', in *Australian Society for Veterinary Pathology Annual Conference*, Launceston, Tas., The Conference, Launceston, Tas.,

Bishop, K. A., Wang, L. F., Eaton, B. T., and Broder, C. C. 2006, 'Characterization of an isoleucine-rich region of the Hendra virus F glycoprotein', in *American Society for Virology 25th Annual Meeting*, University of Wisconsin-Madison, Madison, WI, The Meeting, Madison, WI, pp. 280

Bossart, K. N., McEachern, J. A., Choudhry, V., Dimitrov, D. S., Eaton, B. T., Broder, C. C., and Wang, L. F. 2006, 'Development of a multiplexed micro sphere surrogate neutralization assay for Nipah and Hendra viruses', in *AB-CRC Annual National workshop*, Cairns Colonial Club Resort, Cairns, Qld., The Workshop, Cairns, Qld.,

Bossart, K. N., Mungall, B. A., Middleton, D. J., Bonaparte, M. I., Dimitrov, A. S., Cramer, G. S., Zhu, Z., Dimitrov, D. S., Eaton, B. T., and Wang, L. F. 2006, 'Therapeutic strategies for Henipaviruses', in *7th Asia-Pacific Congress of Medical Virology*, New Delhi, India, The Congress, New Delhi, India,

Bowden, T. R., Babiuk, S., Anderson, M. A., Parkyn, G., Copps, J., Kitching, R. P., and Boyle, D. B. 2006, 'Capripoxvirus tropism and shedding: a quantitative study in experimentally infected sheep and goats', in *2006 FASEB Summer Research Conference Poxviruses*, Hyatt Grand Champions Resort and Spa, Indian Wells, California, USA, The Conference, Indian Wells, California, USA,

Boyle, D. B. and Selleck, P. W. 2006, 'Molecular Diagnosis at AAHL', in *Subregional Training Workshop on Diagnostic Laboratory Techniques for Avian Influenza*, National Reference Laboratory for Poultry Diseases, National Agricultural Research Centre, Islamabad, Pakistan, The Workshop, Islamabad, Pakistan,

Boyle, D. B. and Selleck, P. W. 2006, 'Molecular Diagnosis at AAHL', in *Subregional Training Workshop on Diagnostic Laboratory Techniques for Avian Influenza*, National Avian Influenza Reference Laboratory, Ministry of Agriculture, Harbin, China, The Workshop, Harbin, China,

Butler, J., Kunz, B., Moore, R. J., and Sapats, S. 2006, 'Use of E. Coli as a delivery vector for prophylactic proteins targeted against Infectious Bursal Disease Virus', in *Veterinary Virology Conference: a festschrift to recognise the lifetime achievements of Professor Michael Studdert*, Melbourne, Vic., The Conference, Melbourne, Vic.,

Chua, T. H., Ellis, T. M., Wong, W. C. W., Guan, Y., Ge, S. X., Peng, G., Lamichhane, C., Maliadis, C., Tan, S. W., Selleck, P. W., and Parkinson, J. 2006, 'Evaluation and application of five tests for influenza A or H5 avian Influenza antigen detection in avian species', in *AB-CRC Annual National Workshop*, Cairns Colonial Club Resort, Cairns, Qld., The Workshop, Cairns, Qld.,

Colling, A. and Selleck, P. W. 2006, 'Assay Validation and Quality Control for Diagnostic Tests', in *Subregional Training Workshop on Diagnostic Laboratory Techniques for Avian Influenza*, National Reference Laboratory for Poultry Diseases, National Agricultural Research Centre, Islamabad, Pakistan, The Workshop, Islamabad, Pakistan,

Colling, A. and Selleck, P. W. 2006, 'Assay validation and Quality Control for Diagnostic Tests', in *Subregional Training Workshop on Diagnostic Laboratory Techniques for Avian Influenza*, National Avian Influenza Reference Laboratory, Ministry of Agriculture, Harbin, China, The Workshop, Harbin, China,

Colling, A. and Selleck, P. W. 2006, 'External Quality Assurance Programs', in *Subregional Training Workshop on Diagnostic Laboratory Techniques for Avian Influenza*, National Reference Laboratory for Poultry Diseases, National Agricultural Research Centre, Islamabad, Pakistan, The Workshop, Islamabad, Pakistan,

Colling, A. and Selleck, P. W. 2006, 'External Quality Assurance Programs', in *Subregional Training Workshop on Diagnostic Laboratory Techniques for Avian Influenza*, National Avian Influenza Reference Laboratory, Ministry of Agriculture, Harbin, China, The Workshop, Harbin, China,

Comey, B., Jack, P. J. M., Amos-Ritchie, R. N., Boyle, D. B., and Diallo, I. 2006, 'Identification of selected avian pathogen using microarrays', in *AB-CRC Annual National Workshop*, Cairns Colonial Club Resort, Cairns, Qld., The Workshop, Cairns, Qld.,

Cowled, C., Boyle, D. B., Weir, R., Pritchard, L. I., and Barnard, R. T. 2006, 'Characterisation of novel livestock viruses by genetic sequencing', in *AB-CRC Annual National Workshop*, Cairns Colonial Club Resort, Cairns, Qld., The Workshop, Cairns Qld.,

Cowley, J. A., Walker, P. J., and Wijegoonawardane, P. 2006, 'Biology, genetics and ecology of the YHV complex', in *9th International Colloquium on Invertebrate Pathology and Microbial Control//39th Annual Meeting of the SIP//8th International Conference on Bacillus thuringiensis*, Wuhan, China, Zhihong, H., Ming, S., Ziniu, Y., Junyan, H., Dongmei, H. and Changming, Z., (Eds.), The Conference, Wuhan, China, pp. 50

Cramer, S. G., Hyatt, A. D., Lowther, S. L., van Driel, R., Hutchinson, O. C., and Cunningham, A. A. 2006,

Crowley, T. 2006, 'Microarray analysis of chicken anaemia virus infection', in *International Congress of Immunogenomics and Immunomics: Immunology for the 21st century*, Budapest, Hungary, The Conference, Budapest, Hungary,

Daniels, P. W. 2006, 'The challenge of emerging infectious diseases: What capabilities are needed?', in *National Seminar on Livestock Production and Veterinary technologies*, Bogor, Indonesia, The Seminar, Bogor, Indonesia,

Daniels, P. W. 2006, 'Cultural practices that influence the emergence of Nipah', in *International symposium on Emerging Zoonoses ISEZ 2006: Medical and Veterinary Partnerships to Address Global Challenges*, Atlanta, Georgia, USA, The Symposium, Atlanta, Georgia, USA,

Daniels, P. W. 2006, 'Veterinary aspects of H5N1 and its control', in *Australian Influenza Symposium 2006*, TGA Building, Symonston, Canberra, The Symposium, Symonston, Canberra,

Della-Porta, A. J. 2006, 'Capacity building and biosafety', in *Australian Society for Microbiology Conference*, Gold Coast, QLD., ASM, Gold Coast, QLD.,

Di Rubbo, A., Michalski, W. P., Halpin, K., and Meers, J. 2006, 'Developing diagnostic tools for Pteropid bat serology', in *AB-CRC Annual National Workshop*, Cairns Colonial Club Resort, Cairns, Qld., The Workshop, Cairns, Qld.,

Doran, T. J. 2006, 'Silence of the lambs....chickens.... and cows? Application of gene silencing to viral diseases of livestock', in *Australian Society for Microbiology Conference*, Gold Coast, QLD, The Conference, Gold Coast, QLD,

Doran, T. J. 2006, 'Silence of the lambs...chickens...and cows? Application of Gene Silencing to viral diseases of livestock', in *Deakin University MRU Seminar Series*, Deakin University, Waurn Ponds, Vic., The Seminar, Waurn Ponds, Vic.,

Durr, P. 2006, 'GIS and animal health surveillance systems', in *1st OIE International Conference Use of GIS in veterinary activities*, Silvi Marina (TE) Abruzzo, Italy, The Conference, Abruzzo, Italy,

Eaton, B. T. 2006, 'Advances in diagnostics: implications for the epidemiologist', in *Proceedings of the 11th Symposium of the International Society for Veterinary Epidemiology and Economics*, Cairns, QLD, The symposium, Cairns, QLD,

Field, H. E., Wang, L. F., Zhang, S., Daszak, P., Shi, Z., Smith, C., and Epstein, J. 2006, 'A successful approach to identifying the natural reservoir of SARS', in *ICEID 2006 (International Conference on Emerging Infectious Diseases)*, Atlanta, Georgia, USA, The Conference, Atlanta, Georgia, USA,

Field, H. E., Wang, L. F., Zhang, S., Daszak, P., Smith, C. S., Epstein, J. H., and Shi, Z. 2006, 'Searching for the natural reservoir of the SARS virus', in *Proceedings of the 11th Symposium of the International Society for Veterinary Epidemiology and Economics*, Cairns, QLD., The Symposium, Cairns, QLD,

Fogarty, R., Halpin, K., Mungall, B. A., and Hyatt, A. D. 2006, 'Effects of environmental conditions on Henipavirus survival', in *ICEID 2006 (International Conference on Emerging Infectious Diseases)*, Atlanta, Georgia, USA, The Conference, Atlanta, Georgia, USA,

Foord, A. J., Muller, J., Thalmann, C., Yu, M., and Heine, H. G. 2006, 'Recombinant antibodies for Foot-and Mouth disease virus diagnosis', in *AB-CRC Annual National Workshop*, Cairns Colonial Club Resort, Cairns, Qld., The Workshop, Cairns, Qld.,

Geerlings, K., Williams, D. T., Yu, M., Hansson, E., Wang, L. F., and Mackenzie, J. S. 2006, 'Molecular characterisation of two divergent strains Murray Valley Encephalitis Virus Strains', in *AB-CRC Annual National Workshop*, Cairns Colonial Club Resort, Cairns, Qld., The Workshop, Cairns, Qld.,

Gleeson, L. J., Selleck, P. W., Bingham, J., Lowther, S. L., Trinidad, L., and Heine, H. G. 2006, 'Transmission of H5N1 avian influenza virus A/Muscovy duck/Vietnam/453/2004 to *Anas castanea* (chestnut teal) and Australian native duck', in *6th International Symposium on Avian Influenza*, Cambridge, UK, The Symposium, Cambridge, UK,

Greenall, S. A., Heine, H. G., Fenton, S. P., Johnson, M., Tyack, S. G., and Sapats, S. 2006, 'Passive protection against Chicken Infectious Bursal Disease Virus

through viral delivery of antibody fragments', in *7th International Congress of Veterinary Virology*, Faculdade de Medicina Veterinaria Lisboa, Portugal, European Society for Veterinary Virology, Lisboa, Portugal, pp. 113

Gubala, A., Boyle, D. B., Barnard, R. T., and Proll, D. 2006, 'Relationships and risk assessments of Rhabdoviruses in Australia', in *AB-CRC Annual National Workshop*, Cairns Colonial Club Resort, Cairns, Qld., The Workshop, Cairns, Qld.,

Hall, R. A., Clark, D. C., Cheah, W. Y., Pham, K., Hobson-Peters, J., Toye, P., Bossart, K. N., and Wang, L. F. 2006, 'Serological discrimination between infections caused by exotic flavivirus pathogens and their closely related indigenous cousins', in *AB-CRC Annual National Workshop*, Cairns Colonial Club Resort, Cairns, Qld., The Workshop, Cairns, Qld.,

Halpin, K., Fogarty, R., Middleton, D. J., and Hyatt, A. D. 2006, 'Henipavirus spill-over: how bats might be involved', in *ICEID 2006 (International Conference on Emerging Infectious Diseases)*, Atlanta, Georgia, USA, The Conference, Atlanta, Georgia, USA,

Hammond, J. M. 2006, 'Foot and Mouth Disease and Avian Influenza: Status and diagnostic capability', in *Australia-Indonesia joint symposium on Science and Technology*, Jakarta, Indonesia, The Symposium, Jakarta, Indonesia,

Heine, H. G. and Selleck, P. W. 2006, 'Molecular Diagnosis of Avian Influenza', in *Subregional Training Workshop on Diagnostic Laboratory Techniques for Avian Influenza*, National Reference Laboratory for Poultry Diseases, National Agricultural Research Centre, Islamabad, Pakistan, The Workshop, Islamabad, Pakistan,

Heine, H. G. and Selleck, P. W. 2006, 'Molecular Diagnosis of Avian Influenza', in *Subregional Training Workshop on Diagnostic Laboratory Techniques for Avian Influenza*, National Avian Influenza Reference Laboratory, Ministry of Agriculture, Harbin, China, The workshop, Harbin, China,

Heine, H. G., Trinidad, L., Selleck, P. W., and Lowther, S. L. 2006, 'Rapid detection of Influenza A and differentiation between AI subtypes H5 and H7 by TaqMan RT-PCR', in *6th International symposium on Avian Influenza*, Cambridge, UK, The Symposium, Cambridge, UK,

Hickey, A. C., Mungall, B. A., Bossart, K. N., Bishop, K. A., Eaton, B. T., Wang, L. F., and Broder, C. C. 2006, 'Characterization of the Henipavirus attachment glycoprotein using murine monoclonal antibodies and the identification of a novel neutralization domain', in *American Society for Virology 25th Annual Meeting*, University of Wisconsin-Madison, Madison, WI, The Meeting, Madison, WI, pp. 139

Hinton, T. 2006, 'Development of shRNAi for suppression of Chicken Anaemia Virus replication', in *Veterinary Virology Conference: a festschrift to recognise the lifetime achievements of Professor Michael Studdert*, Melbourne, Vic., The Conference, Melbourne, Vic.,

Hyatt, A. D. 2006, 'A busy time in emerging diseases: the continued role for diagnostic and consultative electron microscopy', in *Glienicke workshop 2006: Diagnostic electron microscopy in infectious diseases*, Robert Koch-Institut (RKI) Berlin, Germany, The Workshop, Berlin, Germany,

Hyatt, A. D. 2006, 'Electron microscopy: a front-line multiplex diagnostic tool for the detection of new and emerging viruses', in *16th International Microscopy Congress*, Sapporo, Japan, The Congress, Sapporo, Japan, pp. 482

Hyatt, A. D. 2006, 'The role of electron microscopy in new & emerging diseases: critical issues', in *ACMM 19 Sydney 2006 Microscopy solutions: Australian Conference on Microscopy and Microanalysis*, AJC Convention Centre, Royal Randwick, Randwick, NSW, Munroe, P., Westwood, R., Eichhorn, U., Hicks, R., Ringer, S.P., Keast, V., Jones, A., Blackford, M. and Stevens-Kalceff, M., (Eds.) , Australian Microscopy and Microanalysis Society, Clayton South, Vic.,

Hyatt, A. D. 2006, 'Working towards objective detection of unknown pathogens via a coordinated, virtual multiplex microscopical platform', in *Microscopy and Microanalysis 2006*, Chicago, Illinois, Cambridge University Press, Chicago, Illinois,

Hyatt, A. D., Chua, K. B., Pritchard, L. I., Wang, L. F., Cummins, D. M., Fogarty, R., and Halpin, K. 2006, 'Not all fusogenic viruses are Henipaviruses', in *ICEID 2006 (International Conference on Emerging Infectious Diseases)*, Atlanta, Georgia, USA, The Conference, Atlanta, Georgia, USA,

Hyatt, A. D., Pallister, J. A., Olsen, V., and Voysey, R. 2006, 'Spin-offs: What have been the direct and indirect outcomes from research into the biological control of cane toads?', in *Science of Cane Toad Invasion and Control: Proceedings of the Invasive animals CRC/CSIRO/Qld NRM&W Cane Toad Workshop*, Rydges, Southbank, QLD, Molloy, K. and Henderson, W., (Eds.) , The Workshop, Rydges, Southbank, QLD, pp. 94-97

Jeggo, M. H. 2006, 'Emerging zoonoses: examining the impact of pathogens that jump species barriers and the intrinsic role of the Australian Animal Health Laboratory', in *Emerging Infectious Disease Control & pandemic preparedness conference*, Carlton Crest Hotel, Sydney, The Conference, Carlton Crest Hotel, Sydney,

Jeggo, M. H. 2006, 'Guarding our door', in *Livestock Saleyards Association Annual Conference*, Geelong, Vic., The Conference, Geelong, Vic,

Jenkins, K. A., Sheedy, S. A., and Bean, A. G. D. 2006, 'The use of cytokines to enhance vaccine efficacy', in *Australian Egg Corporation Ltd Industry Forum PIX2006*, Holiday Inn, Gold Coast, QLD, The Forum, Gold Coast, QLD,

Keyburn, A. L., Sheedy, S. A., Ford, M. E., Williamson, M. M., Awad, M. M., Rood, J. I., and Moore, R. J. 2006, 'The alpha toxin of *Clostridium perfringens* is not an essential virulence factor in necrotic enteritis in chickens', in *Clostrpath 2006: 5th*

International Meeting on the molecular biology and pathogenesis of the clostridia, University of Nottingham, Nottingham, UK, The Meeting, Nottingham, UK,

Kitching, R. P., Hammond, J. M., Jeggo, M. H., Charleston, B., Patton, D., Rodriguez, L., and Heckert, R. 2006, 'Global control of foot-and-mouth disease - is it an option?', in *4th International Veterinary Vaccines and Diagnostics Conference*, National Veterinary Institute, Oslo, Norway, The Conference, Oslo, Norway,

Lowenthal, J. W. 2006, 'New strategies for control of avian influenza', in *9th Avian Immunology Research Group Meeting*, Paris, France, The Meeting, Paris, France,

McEachern, J. A., Bossart, K. N., Hansson, E., Muller, J., and Wang, L. F. 2006, 'Development of multiplexed bead-based diagnostic assays for foot-and-mouth disease virus', in *AB-CRC Annual National Workshop*, Cairns Colonial Club Resort, Cairns, Qld., The Workshop, Cairns, Qld.,

Middleton, D. J. 2006, 'Henipavirus: pathogenesis, spillover and the bat enigma', in *American College of Veterinary Pathologists 57th Annual meeting*, Tucson, Arizona, USA, The Meeting, Tucson, Arizona, USA,

Middleton, D. J. and Selleck, P. W. 2006, 'Avian Influenza - Epidemiology, Clinical Signs, Pathology and Diagnosis', in *Subregional Training Workshop on Diagnostic Laboratory Techniques for Avian Influenza*, National Research Laboratory for Poultry Diseases, National Agricultural Research Centre, Islamabad, Pakistan, The Workshop, Islamabad, Pakistan,

Muller, J., Foord, A. J., Heine, H. G., Yu, M., Wilks, C., and Wang, L. F. 2006, 'Antigenicity studies and development of serological tests for foot-and-mouth disease virus', in *AB-CRC Annual National Workshop*, Cairns Colonial Club Resort, Cairns, Qld., The Workshop, Cairns, Qld.,

Muller, J., Foord, A. J., Heine, H. G., Yu, M., Wilks, C., and Wang, L. F. 2006, 'Antigenicity studies and development of serological tests for foot and mouth disease virus', in *Veterinary Virology Conference: a festschrift to recognise the lifetime achievements of Professor Michael Studdert*, Melbourne, Vic., The Conference, Melbourne, Vic.,

Mungall, B. A., Bossart, K. N., Middleton, D. J., Cramer, G. S., McEachern J.A., Wang, L. F., Eaton, B. T., and Broder, C. C. 2006, 'Vaccination with Nipah or Hendra virus recombinant soluble G glycoprotein protects against Nipah virus challenge in the cat model', in *Keystone Symposia: Cell biology of virus entry, replication and pathogenesis*, Eldorado Hotel & Spa, Santa Fe, New Mexico, USA, Virgin, H.W., Lamb, R.A., Compans, R.W., Doms, R.W. and Oldstone, B.A., (Eds.) , The Symposia, Santa Fe, New Mexico, USA, pp. 52

Mungall, B. A., Middleton, D. J., Cramer, G. S., Bingham, J., Halpin, K., Bossart, K. N., Eaton, B. T., Wang, L. F., and Broder, C. C. 2006, 'Characterization of a feline model of acute Nipah virus infection and protective vaccination with a soluble G

glycoprotein subunit vaccine', in *12th ICID Conference*, Centro de Congressos de Lisboa, The Congress, Lisbon,

Mungall, B. A., Middleton, D. J., Crameri, G. S. , Halpin, K., Eaton, B. T., and Broder, C. C. 2006, 'Vertical transmission and foetal replication of Nipah virus in an experimentally infected cat', in *XIIIth International Conference on Negative Strand Viruses*, Salamanca, Spain, Mahy, B.W.J., Kolakofsky, D. and Villar, E., (Eds.), The Conference, Salamanca, Spain, pp. 180

Pant, G. R. and Selleck, P. W. 2006, 'The status of Avian Influenza in Nepal', in *6th International Symposium on Avian Influenza*, Cambridge, UK, The Symposium, Cambridge, UK,

Rootes, C. L. 2006, 'Lyssavirus infections of Australian bats: a diagnostic perspective', in *Australian Association of Veterinary Laboratory Diagnosticians*, Taronga Zoo, NSW, The Conference, Taronga, NSW,

Selleck, P. W. 2006, 'Establishing FAO Laboratory Networks for Avian Influenza Diagnosis and Surveillance', in *Subregional Training Workshop on Diagnostic Laboratory Techniques for Avian Influenza*, National Reference Laboratory for Poultry Diseases, National Agricultural Research Centre, Islamabad, Pakistan, The Workshop, Islamabad, Pakistan,

Selleck, P. W. 2006, 'Establishing FAO Laboratory Networks for Avian Influenza Diagnosis and Surveillance', in *Subregional Training Workshop on Diagnostic Laboratory Techniques for Avian Influenza*, National Avian Influenza Reference Centre, Ministry of Agriculture, Harbin, China, The Workshop, Harbin, China,

Selleck, P. W. 2006, 'Investigation of Outbreaks of Avian Influenza', in *Subregional Training Workshop on Diagnostic Laboratory Techniques for Avian Influenza*, National Reference Laboratory for Poultry Diseases, National Agricultural Research Centre, Islamabad, Pakistan, The Workshop, Islamabad, Pakistan,

Selleck, P. W. 2006, 'Investigation of Outbreaks of Avian Influenza', in *Subregional Training Workshop on Diagnostic Laboratory Techniques for Avian Influenza*, National Avian Influenza Reference Laboratory, Ministry of Agriculture, Harbin, China, The Workshop, Harbin, China,

Selleck, P. W. 2006, 'Laboratory safety and H5N1 Avian Influenza Virus', in *Inception Workshop Subregional Training Workshop on Diagnostic Laboratory Techniques for Avian Influenza*, Australian Animal Health Laboratory, Geelong, Vic., The Workshop, Geelong, Vic.,

Selleck, P. W. 2006, 'Laboratory Safety and H5N1 Avian Influenza Virus', in *Subregional Training Workshop on Diagnostic Laboratory Techniques for Avian Influenza*, National Reference Laboratory for Poultry Diseases, National Agricultural Research Centre, Islamabad, Pakistan, The Workshop, Islamabad, Pakistan,

Selleck, P. W. 2006, 'Laboratory Safety and H5N1 Avian Influenza Virus', in *Subregional Training Workshop on Diagnostic Laboratory Techniques for Avian Influenza*, National Avian Influenza Research Laboratory, Ministry of Agriculture, Harbin, China, The Workshop, Harbin, China,

Selleck, P. W. 2006, 'Rapid Diagnostic Tests for Avian Influenza', in *Inception Workshop Subregional Training Workshop on Diagnostic Laboratory Techniques for Avian Influenza*, Australian Animal Health Laboratory, Geelong, Vic., The Workshop, Geelong, Vic.,

Selleck, P. W. 2006, 'Rapid Diagnostic Tests for Avian Influenza', in *Subregional Training Workshop on Diagnostic Laboratory Techniques for Avian Influenza*, National Reference Laboratory for Poultry Diseases, National Agricultural Research Centre, Islamabad, Pakistan, The Workshop, Islamabad, Pakistan,

Selleck, P. W. 2006, 'Rapid Diagnostic Tests for Avian Influenza', in *Subregional Training Workshop on Diagnostic Laboratory Techniques for Avian Influenza*, National Avian Influenza Reference Laboratory, Ministry of Agriculture, Harbin, China , The Workshop, Harbin, China,

Selleck, P. W. 2006, 'Serological tests for Avian Influenza', in *Inception Workshop Subregional Training Workshop on Diagnostic Laboratory Techniques for Avian Influenza*, Australian Animal Health Laboratory, Geelong, Vic., The Workshop, Geelong, Vic.,

Selleck, P. W. 2006, 'Serological Tests for Avian Influenza', in *Subregional Training Workshop on Diagnostic Laboratory Techniques for Avian Influenza*, National Research Laboratory for Poultry Diseases, National Agricultural Research Centre, Islamabad, Pakistan, The Workshop, Islamabad, Pakistan,

Selleck, P. W. 2006, 'Serological tests for Avian Influenza', in *Subregional Training Workshop on Diagnostic Laboratory Techniques for Avian Influenza*, National Avian Influenza Reference Laboratory, Ministry of Agriculture, Harbin, China, The Workshop, Harbin, China,

Smith, C. S., Cramer, G. S., de Jong, C., McEachern, J. A., Yu, M., Wang, L. F., and Field, H. E. 2006, 'Investigation of SARS like coronaviruses in bats', in *AB-CRC Annual National Workshop*, Cairns Colonial Club Resort, Cairns, Qld., The Workshop, Cairns, Qld.,

Snelling, H., Mungall, B. A., Bacic, A., and Michalski, W. P. 2006, 'Analysis of N-glycans on structural protein of Nipah and Hendra virus', in *Veterinary Virology Conference: a festschrift to recognise the lifetime achievements of Professor Michael Studdert*, Melbourne, Vic., The Conference, Melbourne, Vic.,

Thalmann, C., Heine, H. G., and Barnard, R. T. 2006, 'Development and production of immunological reagents and tests for emerging infectious diseases using recombinant antibody technology', in *AB-CRC Annual National Workshop*, Cairns

Colonial Club Resort, Cairns, Qld., The Workshop, Cairns, Qld.,

Virtue, E. R., Lai, R., Castillo, L. A., Barnett, G. R., Heine, H. G., and Barnard, R. T. 2006, 'Rapid diagnosis of known and emerging influenzas with human health implications', in *AB-CRC Annual National Workshop*, Cairns Colonial Club Resort, Cairns, Qld., The Workshop, Cairns, Qld.,

Wang, L. F. 2006, 'Bats and paramyxoviruses: a tale of three stories', in *Second Areva-Pasteur Forum: Impact of Behavioral Ecology on Emerging Infectious Diseases*, Shanghai, China, The Forum, Shanghai, China,

Wang, L. F. 2006, 'Bats, Civets, and emergence of SARS', in *10th International Symposium for Zoonoses Control*, Conference Hall, Hokkaido University, Hokkaido, Japan, The Symposium, Hokkaido, Japan,

Wang, L. F. 2006, 'Bats, civets and emergence of SARS', in *Deakin University MRU Seminar series*, Deakin University, Waurn Ponds, Vic., Deakin University, Waurn Ponds, Vic.,

Wang, L. F. 2006, 'SARS and Bats', in *International symposium on Emerging Zoonoses ISEZ 2006: Medical and Veterinary Partnerships to Address Global Challenges*, Atlanta, Georgia, USA, The Symposium, Atlanta, Georgia, USA,

Wang, L. F., Shi, Z., Zhang, S., Field, H. E., Daszak, P., and Eaton, B. T. 2006, 'From civet cats to horseshoe bats: tracing the origin of SARS', in *ICEID Conference*, Atlanta, Georgia, USA, The Conference, Atlanta, Georgia, USA,

Weir, R., Walsh, S., Jack, P., Melville, L., and Boyle, D. B. 2006, 'Is a virus isolated in the Northern Territory a member of the Californian Encephalitis', in *Australian Biosecurity CRC Meeting*, Cairns, QLD, The Meeting , Cairns, QLD,

Weir, R., Walsh, S., Jack, P. J. M., Melville, L., and Boyle, D. B. 2006, 'Is virus isolated in the Northern Territory a member of the California Encephalitis?', in *AB-CRC Annual National Workshop*, Cairns Colonial Club Resort, Cairns, Qld., The Workshop, Cairns, Qld.,

Yaiw, K. C., Chen, J. M., Yu, M., Bingham, J., Bowden, T. R., Cramer, G. S., Selleck, P. W., Wang, L. F., Devi, S., and Wong, K. T. 2006, 'Development of TaqMan real-time PCR and comparative ELISA for the detection of Tioman virus infection', in *7th Asia-Pacific Congress of Medical Virology*, New Delhi, India, The Congress, New Delhi, India,

Yu, M., Shi, Z., Cramer, G. S., McEachern, J. A., and Wang, L. F. 2006, 'Susceptibility of engineered cell lines of infection by SARS-CoV and SARS-like-CoV', in *AB-CRC Annual National Workshop*, Cairns Colonial Club Resort, Cairns, Qld., The Workshop, Cairns, Qld.,

Dissertations

Butler, J.M. (2006) A novel approach to the prevention of viral infection. Deakin University.

Journal Articles

Andrew, M. E., Morris, K. R., Coupar, B. E. H., Sproat, K. W., Oke, P. G., Bruce, M. P., Broadway, M. M., Morrissy, C. J. & Strom, A. D. G. 2006, 'Porcine interleukin-3 enhances DNA vaccination against classical swine fever', *Vaccine*, vol. 24, 16, pp. 3241-3247.

Bossart, K. N. & Broder, C. C. 2006, 'Developments towards effective treatments for Nipah and Hendra virus infection', *Expert reviews in anti-infective therapy*, vol. 4, 1, pp. 43-52.

Boyle, D. B. 2006, 'At the frontline of disease detection', *Livestock horizons*, vol. 2, 2, pp. 18-9.

Capua, I., Brown, I., Johnson, M. A., Senne, D. & Swayne, D. 2006, 'Veterinary virologists share avian flu data', *Science*, vol. 312, 5780, pp. 1597

Chen, J. M., Yu, M., Morrissy, C. J., Zhao, Y. G., Meehan, G., Sun, Y. X., Wang, Q. H., Zhang, W., Wang, L. F. & Wang, Z. L. 2006, 'A comparative indirect ELISA for the detection of Henipavirus antibodies based on a recombinant nucleocapsid protein expressed in *Escherichia coli*.' , *Journal of Virological Methods*, vol. 136, 1-2, pp. 273-276.

Coupar, B. E. H., Purcell, D., Thomson, S., Ramshaw, I., Kent, S. J. & Boyle, D. B. 2006, 'Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials', *Vaccine*, vol. 24, 9, pp. 1378-1388.

De Rose, R., Sullivan, M. T., Dale, C. J., Kelleher, A. D., Emery, S., Cooper, D. A., Ramshaw, I. A., Boyle, D. B., Kent, S. J. & Australian Thai HIV Vaccine Consortium 2006, 'Dose-response relationship of DNA and recombinant fowlpox virus prime-boost HIV vaccines: implications for future trials', *Human vaccines*, vol. 2, 3, pp. 134-136.

Eaton, B. T. 2006, 'Batter up against animal viruses', *Farming ahead with Kondinin group*, vol. 171, pp. 25

Eaton, B. T., Broder, C. C., Middleton, D. J. & Wang, L. F. 2006, 'Hendra and Nipah viruses: different and dangerous', *Nature reviews microbiology*, vol. 4, 1, pp. 23-35.

Epstein, J. H., Rahman, S. A., Zambriski, J. A., Halpin, K., Meehan, G., Aziz, A. J., Hassan, S. S., Field, H. E., Hyatt, A. D. & Daszak, P. 2006, 'Feral cats and risk for Nipah virus transmission', *Emerging Infectious Diseases*, vol. 12, 7, pp. 1178-1179.

Foord, A. J., Heine, H. G., Pritchard, L. I., Lunt, R. A., Newberry, K. M., Rootes, C. L. & Boyle, D. B. 2006, 'Molecular diagnosis of Lyssaviruses and sequence comparison of Australian bat Lyssavirus samples', *Australian Veterinary Journal*, vol. 84, 7, pp. 225-230.

Hagmaier, K., Stock, N., Goodbourn, S., Wang, L. F. & Randall, R. 2006, 'A single amino acid substitution in the V protein of Nipah virus alters its ability to block interferon signalling in cells from different species', *Journal of general virology*, vol. 87, 12, pp. 3649-3653.

Hammond, J. M. 2006, 'How FMD would devastate Australia', *Livestock horizons*, vol. 2, 2, pp. 12-13.

Harrison, J. M., Bertram, E. M., Boyle, D. B., Coupar, B. E. H., Ranasinghe, C. & Ramshaw, I. A. 2006, '4-1BBL coexpression enhances HIV-specific CD8 T cell memory in a poxvirus prime-boost vaccine', *Vaccine*, vol. 24, 47-48, pp. 6867-6874.

Heine, H. G., Trinidad, L., Selleck, P. W. & Lowther, S. 2006, 'Rapid detection of highly pathogenic avian influenza H5N1 by TaqMan RT-PCR', *Avian Diseases*, vol. Online,

Henry, D. A. 2006, 'Developing a model to manage major disease outbreaks', *Livestock Horizons*, vol. June, pp. 16-17.

Hurt, A. C., Hansbro, P. M., Selleck, P. W., Olsen, B., Minton, C., Hampson, A. W. & Barr, I. G. 2006, 'Isolation of avian influenza viruses from two different transhemispheric migratory shorebird species in Australia', *Archives of Virology*, vol. 151, 11, pp. 2301-2309.

Hyatt, A. D. 2006, 'Working towards objective detection of unknown pathogens via a coordinated virtual multiplex microscopical platform', *Microscopy and Microanalysis*, vol. 12, Suppl. 2, pp. 342-343.

Jack, P. J. M. & Boyle, D. B. 2006, 'DNA Microarrays for pathogen detection and characterization', *Microbiology Australia*, vol. 27, 2, pp. 68-9.

Jeggo, M. H. 2006, '21 years of achievement: Australia's Animal Health Laboratory', *Livestock horizons*, vol. 2, 2, pp. 6-7.

Kelleher, A. D., Puls, R. L., Bebbington, M., Boyle, D. B., Ffrench, R., Kent, S. J., Kippax, S., Purcell, D. F. J., Thomson, S., Wand, H., Cooper, D. A. & Emery, S. 2006, 'A randomised, placebo-controlled phase 1 trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1', *Aids*, vol. 20, 2, pp. 294-7.

Kurath, G., Garver, K. A., Corbeil, S., Elliot, D. G., Anderson, E. D. & LaPatra, S. E. 2006, 'Protective immunity and lack of histopathological damage two years after DNA vaccination against infectious hematopoietic necrosis virus in trout', *Vaccine*, vol. 24, 3, pp. 345-354.

Lambeth, L. S., Wise, T. G., Moore, R. J., Muralitharan, M. S. & Doran, T. J. 2006, 'Comparison of bovine RNA polymerase III promoters for short hairpin RNA expression', *Animal Genetics*, vol. 37, 4, pp. 369-372.

Li, Z., Yu, M., Zhang, H., Magoffin, D. E., Jack, P. J. M., Hyatt, A. D., Wang, H. Y. & Wang, L. F. 2006, 'Beilong virus, a novel paramyxovirus with the largest genome of non-segmented negative-strand RNA viruses', *Virology*, vol. 346, 1, pp. 219-28.

Lowenthal, J. W. 2006, 'Bird flu virus under spotlight', *Farming ahead with Kondinin group*, vol. 168, pp. 36

Lowenthal, J. W. 2006, 'Researching how bird flu crosses to humans', *Livestock horizons*, vol. 2, 2, pp. 21

Lunt, R. A. 2006, 'Rabies and Lyssavirus: an Australian diagnostic perspective', *Australian journal of medical science*, vol. 27, 1, pp. 20-5.

Magoffin, D. E., Halpin, K., Rota, P. A. & Wang, L. F. 2006, 'Effects of single amino acid substitutions at the E residue in the conserved GDNE motif of the Nipah virus polymerase L protein', *Archives of Virology*, vol. online,

Mungall, B. A., Middleton, D. J., Crameri, G. S., Bingham, J., Halpin, K., Russell, G., Green, D., McEachern, J. A., Pritchard, L. I., Eaton, B. T., Wang, L. F., Bossart, K. N. & Broder, C. C. 2006, 'A feline model of acute Nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine', *Journal of Virology*, vol. 80, 24, pp. 12293-12302.

Pant, G. & Selleck, P. W. 2006, 'Surveillance for Avian Influenza in Nepal', *Avian Diseases*, vol. Online,

Pant, G. R. 2006, 'A serological survey of pigs, horses and ducks in Nepal for evidence of infection with Japanese Encephalitis Virus', *annals of the New York Academy of Sciences*, vol. 1081, pp. 124-129.

Pant, G. R., Lunt, R. A., Rootes, C. L., Newberry, K. M. & Daniels, P. W. 2006, 'Serological evidence for Japanese Encephalitis and West Nile Viruses in domestic animals of Nepal', *Comparative Immunology, Microbiology and Infectious Diseases*, vol. 29, 2/3, pp. 166-175.

Pritchard, L. I., Chua, K. B., Cummins, D. M., Hyatt, A. D., Crameri, G. S., Eaton, B. T. & Wang, L. F. 2006, 'Pulau virus: a new member of the Nelson Bay Orthoreovirus species isolated from fruit bats in Malaysia', *Archives of Virology*, vol. 151, pp. 229-239.

Ranasinghe, C., Medveczky, J. C., Woltring, D., Gao, K., Thomson, S., Coupar, B. E. H., Boyle, D. B., Ramsay, A. J. & Ramshaw, I. A. 2006, 'Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against hiv-1', *Vaccine*, vol. 24, 31-32, pp. 5881-5895.

Ren, W., Li, W., Yu, M., Hao, P., Zhou, P., Zhang, S., Zhao, G., Zhong, Y., Wang, S., Wang, L. F. & Shi, Z. 2006, 'Full-length genome sequences of two SARS-like coronaviruses in horseshoe bats and genetic variation analysis', *Journal of General Virology*, vol. 87, pp. 3355-3359.

Selleck, P. W. 2006, 'CSIRO boosts the fight against bird flu', *Livestock horizons*, vol. 2, 2, pp. 20-1.

Sendow, I., Field, H. E., Curran, J., Darminto, Morrissy, C. J., Meehan, G., Buick, T. & Daniels, P. W. 2006, 'Henipavirus in Pteropus vampyrus Bats, Indonesia', *Emerging Infectious Diseases*, vol. 12, 4, pp. 711-2.

Tachedjian, M., Yu, M., Lew, A. M., Rockman, S., Boyle, J. S., Andrew, M. E. & Wang, L. F. 2006, 'Molecular cloning and the characterization of pig, cow and sheep MAdCAM-1 cDNA and the demonstration of cross-reactive epitopes amongst mammalian homologues', *Tissue antigens*, vol. 67, 5, pp. 419-426.

Thyer, J., Unal, A., Hartel, G., Middleton, D. J., Bingham, J., Braun, M., Uren, E. & Maher, D. 2006, 'Investigation of Prion removal/inactivation from chromatographic gel', *Vox Sanguinis*, vol. 91, 4, pp. 301-308.

Thyer, J., Unal, A., Thomas, P., Eaton, B. T., Bhashyam, R., Ortenburg, J., Uren, E., Middleton, D. J., Selleck, P. W. & Maher, D. 2006, 'Prion-removal capacity of chromatographic and ethanol precipitation steps used in the production of albumin and immunoglobulins', *Vox Sanguinis*, vol. 91, 4, pp. 292-300.

Unal, A., Thyer, J., Uren, E., Middleton, D. J., Braun, M. & Maher, D. 2006, 'Investigation by bioassay of the efficacy of sodium hydroxide treatment on the inactivation of mouse-adapted scrapie', *Biologicals*, vol. online,

Wang, L. F. 2006, 'Bats found to be the natural host of SARS', *Livestock horizons*, vol. 1, 3, pp. 17

Wang, L. F. 2006, 'New virus named after Geelong', *Livestock horizons*, vol. 2, 2, pp. 9

Wang, L. F., Shi, Z., Zhang, S., Field, H., Daszak, P. & Eaton, B. T. 2006, 'Review of bats and sars', *Emerging Infectious Diseases*, vol. 12, 12 , pp. 1834-1840.

Zhang, S., Shi, Z., Field, H. E., Daszak, P., Eaton, B. T. & Wang, L. F. 2006, 'Voucher specimens for SARS-linked bats - response', *Science*, vol. 311, 5764, pp. 1099-1100.

Zhu, Z., Dimitrov, A. S., Bossart, K. N., Crameri, G. S., Bishop, K. A., Choudry, V., Mungall, B. A., Feng, Y. R., Choudhary, A., Zhang, M. Y., Feng, Y., Wang, L. F., Xiao, X., Eaton, B. T., Broder, C. C. & Dimitrov, D. S. 2006, 'Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies', *Journal of virology*, vol. 80, 2, pp. 891-9.

(B) Human Protection and Performance Division, Defence Science Technology Organisation (DSTO)

The policy of the Defence Science and Technology Organisation is to publish results of a general scientific value in the open literature. Information that is more specialised and relevant particularly to defence is published in laboratory reports, which are unclassified and available to the public, unless they contain information that might prejudice the security of Australia or information that is commercial-in-confidence. It is envisaged that all results of the biological research will be either unclassified or “commercial-in-confidence”.

The Defence Health Service Branch (DHSB) encourages the publication of scientific reviews of the literature in the biological defence area. Over the past 12 months, several articles have been published or accepted for publishing in the Australian and international scientific literature. These include:

Dawson, R. M., Alderton, M. R., Gauci, P. J. and McDonnell, M. B. 2006. The effect of cell disruption on the sensitivity of immunoassays for anthrax and plague vaccines. DSTO-TR-1890.

Dunworth, T., Mathews, R.J. and McCormack, T.L.H., ‘National Implementation of the Biological Weapons Convention’ (2006) 11 *Journal of Conflict and Security Law* 93-118.

Gubala, A. J. , Proll, D. F. (2006) Molecular-Beacon Multiplex Real-Time PCR Assay for detection of *Vibrio Cholerae*, *Applied and Environmental Microbiology* 2006, 72(9), 6424-6428.

Hartley, P.G., Alderton, M. R., Dawson, R. M. and Wells, D. 2006. Monovalent and polyvalent carbohydrate inhibitors of ricin binding to a model of the cell-surface receptor. *Journal of Applied Toxicology*, 2006, 26, 247-252.

Mathews, R.J. and Samihardjo, I., ‘Report of the Biological Weapons Convention (BWC) Regional Workshops Co-hosted by Indonesia and Australia – Submitted by Australia and Indonesia’. Working Paper presented to the Sixth BWC Review Conference, 20 November – 8 December 2006, BWC/Conf.VI/WP.34 (28 November 2006).

Paddle, B. M., Wong, V. K. and Muller B. D. 2006 The cytotoxic effect of anthrax lethal toxin on human lung cells in vitro and the protective action of bovine antibodies to PA and LF. *Journal of Applied Toxicology*. 2006, 26(2), 162-168.

(C) The National High Security Laboratory (NHSQL)

The National High Security Laboratory (NHSQL) operates under the auspices of the Victorian Infectious Diseases Reference Laboratory (VIDRL). The laboratory only carries out a limited number of research activities that result in publication.

Kaye, M., Druce, J., Tran, T., Kostecky, R., Chibo, D., Morris, J., Catton, M. and Birch, C. 2006 SARS – associated Coronavirus Replication in Cell Lines. *Emerging Infectious Diseases*, 2006, 12(1), 128-133.

Tan, T., Tan, Y.X., Tham, P.Y., Gunalan, V., Druce, J., Birch, C., Catton, M., Yu, V. and Tan, Y.J. 2007 The induction of apoptosis by the Severe Acute Respiratory Syndrome (SARS)-coronavirus 7a protein is dependent on its interaction with the Bcl-XL protein. *Journal of Virology*.

Active promotion of contacts

Australia’s submissions with respect to the information sought under Form D (Part 1a-g) and Form D (Part 2) are at **Attachments 5.1** and **5.2**, respectively.

1. Planned international conferences, symposia, seminars, and other similar forums for exchange

For each such event, the following information should be provided:

- a. name of the conference, etc.
- b. arranging organization(s), etc.
- c. time
- d. place
- e. main subject(s) for the conference, etc.
.....
- f. conditions for participation
- g. point of contact for further information, registration, etc.
.....
.....

2. Information regarding other opportunities

.....
.....
.....

Active promotion of contacts

Australia welcomes *bona fide* professional contact with other researchers in matters directly related to the Biological Weapons Convention. Contact should be made with the facility described in Form A, part 2 (iii).

1. Planned international conferences, symposia, seminars, and other similar fora in which Australia participated in 2006

- a. The Technical Cooperation Program (TTCP) CBD Group, Technical Panel 4 - Medical countermeasures against biological agents.
- b. DSTO, Melbourne
- c. November 2006
- d. Australia
- e. TTCP Biological Defence programs, collaborative research, advances in biotechnology
- f. Membership of TTCP CBD Group
- g. Dr Peter Gray, Human Protection & Performance Division, 506 Lorimer Street, Fishermans Bend, Melbourne 3207, Australia. Phone (03) 9626 8482, Fax (03) 9626 8410.

- a. The Technical Cooperation Program (TTCP) CBD Group, Technical Panel 10 - Detection of Biological Agents.
- b. DSTL, Porton Down.
- c. October 2006
- d. United Kingdom
- e. TTCP Biological Defence programs, collaborative research, advances in biotechnology
- f. Membership of TTCP CBD Group
- g. Dr Malcolm Alderton, Human Protection & Performance Division, 506 Lorimer Street, Fishermans Bend, Melbourne 3207, Australia. Phone (03) 9626 8420, Fax (03) 9626 8410.

- a. The Technical Cooperation Program (TTCP) CBD Group, Technical Panel 11 – Integrated NBC Protective Clothing
- b. DRDC, Suffield
- c. September 2006
- d. Canada
- e. TTCP programs, collaborative agreements, advances in personnel protective ensembles
- f. Membership of TTCP CBD Group
- g. Mr Steven Scanlan, Human Protection & Performance Division, 506 Lorimer Street, Fishermans Bend, Melbourne 3207, Australia. Phone (03) 9626 8473, Fax (03) 9626 8342

- a. The Technical Collaboration Program (TTCP), Action Group 51 (AG51) – Rapid Diagnostics
- b. DRDC, Suffield
- c. January 2006
- d. Canada
- e. National programs, terms of reference, nature of collaboration, goals of AG51, timeframe for deliverables of AG51
- f. Membership of TTCP CBD Group
- g. Dr Matthias Dorsch, Human Protection & Performance Division, 506 Lorimer Street, Fishermans Bend, Melbourne 3207, Australia. Phone +61 (3) 9626 8006, Fax +61 (3) 9626 8410

- a. The Technical Collaboration Program (TTCP), Action Group 51 (AG51) – Rapid Diagnostics
- b. DSTO, Melbourne
- c. November 2006
- d. Australia
- e. National programs, terms of reference, nature of collaboration, goals of AG51, timeframe for deliverables of AG51
- f. Membership of TTCP CBD Group
- g. Dr Matthias Dorsch, Human Protection & Performance Division, 506 Lorimer Street, Fishermans Bend, Melbourne 3207, Australia. Phone +61 (3) 9626 8006, Fax +61 (3) 9626 8410

- a. The Technical Cooperation Program (TTCP) CBD Group, Technical Panel 9 - Hazard Assessment.
- b. DTRA, Salt Lake City (moved from San Diego).
- c. February 2006
- d. Canada
- e. TTCP Biological Defence programs, collaborative research, advances in biotechnology
- f. Membership of TTCP CBD Group
- g. Dr Ralph Gailis, Human Protection & Performance Division, 506 Lorimer Street, Fishermans Bend, Melbourne 3207, Australia. Phone (03) 9626 8455, Fax (03) 9626 8410.

Active promotion of contacts**2. Information regarding other opportunities**

- a. The Technical Collaboration Program (TTCP), Action Group 51 (AG51) – Rapid Diagnostics
- b. DTRA, Baltimore
- c. April 2007
- d. United States
- e. National programs, terms of reference, nature of collaboration, goals of AG51, timeframe for deliverables of AG51
- f. Membership of TTCP CBD Group
- g. Dr Matthias Dorsch, Human Protection & Performance Division, 506 Lorimer Street, Fishermans Bend, Melbourne 3207, Australia. Phone +61 (3) 9626 8006, Fax +61 (3) 9626 8410

- a. The Technical Cooperation Program (TTCP) CBD Group, Technical Panel 4 - Medical countermeasures against biological agents.
- b. DSTL, Porton Down
- c. November 2007
- d. United Kingdom
- e. TTCP Biological Defence programs, collaborative research, advances in biotechnology
- f. Membership of TTCP CBD Group
- g. Dr Peter Gray, Human Protection & Performance Division, 506 Lorimer Street, Fishermans Bend, Melbourne 3207, Australia. Phone (03) 9626 8482, Fax (03) 9626 8410.

- a. The Technical Cooperation Program (TTCP) CBD Group, Technical Panel 10 - Detection of Biological Agents.
- b. DTRA, Maryland
- c. October 2007
- d. United States
- e. TTCP Biological Defence programs, collaborative research, advances in biotechnology
- f. Membership of TTCP CBD Group
- g. Dr Malcom Alderton, Human Protection & Performance Division, 506 Lorimer Street, Fishermans Bend, Melbourne 3207, Australia. Phone (03) 9626 8420, Fax (03) 9626 8410.

Active promotion of contacts

- a. The Technical Cooperation Program (TTCP) CBD Group, Technical Panel 11 – Integrated NBC Protective Clothing
- b. DSTO, Melbourne
- c. September 2007
- d. Australia
- e. TTCP programs, collaborative agreements, advances in personnel protective ensembles
- f. Membership of TTCP CBD Group
- g. Dr Rebecca McCallum, Human Protection & Performance Division, 506 Lorimer Street, Fishermans Bend, Melbourne 3207, Australia. Phone (03) 9626 8462, Fax (03) 9626 8410

- a. The Technical Collaboration Program (TTCP), Action Group 51 (AG51) – Rapid Diagnostics
- b. Dstl, Porton Down
- c. September 2007
- d. United Kingdom
- e. National programs, terms of reference, nature of collaboration, goals of AG51, timeframe for deliverables of AG51
- f. Membership of TTCP CBD Group
- g. Dr Matthias Dorsch, Human Protection & Performance Division, 506 Lorimer Street, Fishermans Bend, Melbourne 3207, Australia. Phone +61 (3) 9626 8006, Fax +61 (3) 9626 8410

- a. The Technical Cooperation Program (TTCP) CBD Group, Technical Panel 9 - Hazard Assessment.
- b. DSTL, Porton Down
- c. February 2007
- d. United Kingdom
- e. TTCP Biological Defence programs, collaborative research, advances in biotechnology
- f. Membership of TTCP CBD Group
- g. Dr Ralph Gailis, Human Protection & Performance Division, 506 Lorimer Street, Fishermans Bend, Melbourne 3207, Australia. Phone (03) 9626 8455, Fax (03) 9626 8410.

Declaration of legislation, regulations and other measures

Relating to	Legislation	Regulations	Other measures	Amended since last year
(a) Development, production, acquisition or retention of microbial or other biological agents, or toxins, weapons, equipment and means of delivery specified in Article I	Yes	Yes	No	No
(b) Exports of micro-organisms* and toxins	Yes	Yes	Yes	No
(b) Imports of micro-organisms* and toxins	Yes	Yes	No	No

In addition to the above summary, an overview of key Australian Government legislation relevant to the BWC is provided below:

Background

Australia has the following Australian Government legislation, regulations and other measures to declare under this confidence-building measure. Australia has taken a range of legislative and executive measures that ensure compliance with the UN Security Council Resolution 1540 (2004).

Australia is fully committed to the work of the 1540 Committee in ensuring global implementation of this resolution. As well as WMD-dedicated legislation, there is a considerable amount of health, safety and environmental legislation that control access to hazardous biological materials. The Australian Government is reviewing all WMD and hazardous materials controls, with a view to enhancing them if necessary for counter-terrorism purposes.

Chemical Weapons (Prohibition) Act 1994 and associated regulations

The Act, administered by the Australian Safeguards and Non-Proliferation Office within the Department of Foreign Affairs and Trade, gives effect to Australia’s obligations to the

Convention on the Prohibition of the Development, Production, Stockpiling and Use of Chemical Weapons and on their Destruction. The Act controls certain chemicals which may be used as weapons, including the natural toxins ricin and saxitoxin. The Act's general purpose criterion also applies to the hostile use of any chemical, including other toxins.

The Act extends to the acts of Australian citizens outside Australia. Contravention of the Act is an indictable offence.

CONFIDENCE BUILDING MEASURE E

[Form E continued]

Declaration of legislation, regulations and other measures

Convention on the Prohibition of the Development, Production, Stockpiling and Use of Chemical Weapons and on their Destruction. The Act controls certain chemicals which may be used as weapons, including the natural toxins ricin and saxitoxin. The Act's general purpose criterion also applies to the hostile use of any chemical, including other toxins. The Act extends to the acts of Australian citizens outside Australia. Contravention of the Act is an indictable offence.

Crimes (Biological Weapons) Act 1976

The Act, which is administered by the Attorney-General, makes it unlawful for Australians to develop, produce, stockpile or otherwise acquire or retain microbial or other biological agents or toxins whatever their origin or method of production, of types and in quantities that have no justification for prophylactic, protective or other peaceful purposes; or weapons, equipment or means of delivery designed to use such agents or toxins for hostile purposes or in armed conflict. The Act extends to the acts of Australian citizens outside Australia. Contravention of the Act is an indictable offence.

Crimes (Biological Weapons) Regulations 1980

The Regulations specify the way in which substances acquired under the Act should be stored, disposed of and analysed.

Customs Act 1901 and Customs (Prohibited Exports) Regulations

Under the Customs (Prohibited Export) Regulations the Minister for Defence controls, through a system of export licenses, the export of defence and related goods from Australia. These Regulations were amended in December 1996 to bring all export licensing requirements for defence and related goods under a single regulation - Regulation 13E. No substantial change was made to the regulations relating to the export licensing requirement for biological agents, toxins or equipment which could be used to assist a biological weapons program.

The Regulations require exporters to obtain a licence before proceeding to export certain listed items. These goods are listed in the "Defence and Strategic Goods List". Part 1 of this list includes biological agents designed or adapted to produce casualties in human beings; equipment designed or adapted for disseminating biological agents; goods designed or adapted for the

detection, identification or defence against biological agents; and goods including software designed or adapted for the purposes of producing any of the previous items. Part 3 of the list includes human pathogens and toxins, animal pathogens, plant pathogens and equipment capable of being used to develop biological weapons.

Declaration of legislation, regulations and other measures

Quarantine Act 1908 and associated regulations

The Quarantine Act 1908 is designed to prevent the introduction of serious pests and diseases affecting humans, plants and animals into Australia. Accordingly, in conjunction with the Biological Control Act (see below), it controls the import into Australia of all biological material and may prohibit the import in some circumstances.

The Australian Government has responsibility for quarantine under the Australian Constitution. Responsibility for human quarantine is administered by the Minister for Health and Ageing through the *Quarantine Act 1908* (the Act). Responsibility for plant and animal quarantine is administered by the Minister for Agriculture, Fisheries and Forestry through the Act. All biological agents require prior permission to import. Under the provisions of Section 13 of the Quarantine Act 1908, goods of biological origin, including human pathogenic micro-organisms and toxins, may only be imported into Australia if approval has been given by a Director of Quarantine (Animal/Plant or Human). In giving approval, the Director may require that the importer adhere to certain conditions or requirements, including, but not limited to, the storage, transportation, distribution and disposal of the goods, the use to which the goods may be put, and the personnel authorised to handle or use the goods.

Import conditions vary depending on the nature of the organisms, and on the risks involved. High risk organisms such as serious pathogens of humans, animals and plants which might be considered as potential biological weapons would only be permitted under the most stringent, high security conditions. Very few such imports are approved, and generally those would be for diagnostic research in preparation for emergency responses to specific serious exotic disease incursions.

Penalties for the importation of controlled goods without a permit, and for breaches of permit requirements, are severe and may include a fine, imprisonment or both.

Biological Control Act 1984 and associated regulations

This Act is administered jointly by the Bureau of Rural Sciences and the Agriculture Industry Division of the Department of Agriculture, Fisheries and Forestry within the framework of the Federal Government's quarantine policy. It provides powers additional to those of the

Quarantine Act in order to regulate the release of biological agents for the control of pests, diseases and weeds. It primarily covers issues of compensation for the release of a biological control agent.

Declaration of legislation, regulations and other measures

Gene Technology Act 2000 and associated regulations

The object of the Act is to protect the health and safety of people and the environment from risks posed by, or as a result of, gene technology by identifying those risks and managing them by regulating certain dealings with genetically modified organisms (GMOs). Dealings include manufacturing, importing or conducting experiments with GMOs and require authorisation under legislation. In addition, there are legislative provisions for accreditation of organisations, certification of facilities and extensive monitoring and enforcement powers.

Therapeutic Goods Act 1989 and associated regulations

The Therapeutic Goods Administration of the Australian Government Department of Health and Ageing regulates therapeutic goods for human use under this Act. The Act covers the import and export of therapeutic goods and would include pathogenic micro-organisms where these are included in vaccines for human use.

Prior to initial supply for human use products must be entered in the Australian Register of Therapeutic Goods. Vaccines are registrable products and undergo evaluation by the Therapeutic Goods Administration prior to entry in the Register.

Weapons of Mass Destruction (Prevention of Proliferation) Act 1995 and associated regulations

The Act is administered by the Department of Defence and complements the existing barriers contained in the Customs Act 1901 and the Customs (Prohibited Exports) Regulations. It prohibits the supply or export of goods, not otherwise controlled by the Customs Act 1901, or the provision of services, in circumstances where the goods or services may be used to assist in the development, production, acquisition or stockpiling of WMD, including biological weapons or their delivery systems. The prohibitions under the legislation apply where the person involved knows or suspects the connection with a biological weapons program.

The Act applies extraterritorially as well as within Australia, covering the activities of Australian citizens or residents, as well as bodies incorporated in Australia. It provides a mechanism for exporters to obtain written guidance from the Government on the risk of a particular planned transaction contributing to a biological weapons program.

Declaration of legislation, regulations and other measures**Guidelines to prevent the inadvertent supply of biological weapons-applicable plant, equipment source cultures and expertise**

The Guidelines are a non-statutory, non-proliferation measure, developed by the Department of Foreign Affairs and Trade, to raise the awareness of industry and researchers about the risk of inadvertent involvement in the biological weapons programs of other countries. The Guidelines have been circulated to biological industry, universities, relevant professional associations and government agencies.

Declaration of past activities in offensive and/or defensive biological research and development programmes

In addition to the following information, see **Attachment 6** for explanation of research related to biological warfare defence in Australia.

1. Date of entry into force of the Convention for the State party.

5 October 1977

2. Past offensive biological research and development programmes:

- YES – NO

No

- Period(s) of activities

Not applicable

- Summary of the research and development activities indicating whether work was performed concerning production, test and evaluation, weaponization, stockpiling of biological agents, the destruction programme of such agents and weapons, and other related research.

Not applicable, but see Attachment 6.

3. Past defensive biological research and development programmes:

- YES – NO

No

- Period(s) of activities

No, but see Attachment 6.

- Summary of the research and development activities indicating whether or not work was conducted in the following areas: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination, and other related research, with location if possible.

No, but see Attachment 6.

Declaration of past activities in offensive and/or defensive biological research and development programmes

**EXPLANATORY STATEMENT
RESEARCH AND DEVELOPMENT PROGRAMS RELATED TO
BIOLOGICAL WARFARE AND DEFENCE IN AUSTRALIA
SINCE 1 JANUARY 1946**

Between 1946 and 1994, Australia had no R&D program specifically aimed at defence against biological and toxin weapons. However, some methods for protection against chemical warfare agents could also be used to protect against biological agents. As Australia has had a longstanding R&D program to develop protection against chemical agents, it had, though only incidentally, also been involved in the development of means capable of offering some protection from biological weapons.

The Position at the end of World War II

During World War II, Australia acquired a protective capability against chemical and biological warfare (CBW), which included the equipping of military units with protective clothing, respirators, detection apparatus and decontamination equipment. This capability was associated with the threat of chemical warfare, as almost all of the major combatants possessed chemical weapons.

Australia had no biological weapons and knew little about them. While a need for some defence against them was generally perceived, no major specific steps were taken to achieve this. The tendency was to regard chemical and biological weapons as a single category of threat, with biological weapons treated as the lesser element.

The Situation from 1945 to the 1970s

In the late 1940s and 1950s Defence committees assessed the need for defence against biological agents. The view adopted was that if biological threat arose, Defence authorities would co-opt staff from public health facilities who were trained in microbiology and biological sciences.

In this Australia received limited information on biological defence from the United States of America, the United Kingdom and Canada through the Technical Cooperation Program (TTCP). Under TTCP, there is provision for collaborative research on biological defence, but Australia never participated in that research.

During the 1960s and 1970s some research was conducted in an Australian Defence laboratory on toxins and venoms from Australian animals and plants. The research had no biological warfare focus, and was undertaken solely for the purpose of developing expertise in toxicology. The results of the research were published in scientific journals, contributing to the open scientific literature.

Declaration of past activities in offensive and/or defensive biological research and development programmes

The Situation from 1970 to 1994

During this period the policy was to maintain a watching brief on developments in biological warfare defence research so that a competency could be maintained to advise on policy and to give direction to training for the Australian Defence Force. This competency was derived from open literature and from Australia's partners under The Technical Cooperation Program (TTCP). No research on defence against toxins (or other biological warfare agents) was undertaken during this period.

Australia did, however, maintain an R&D program into chemical defence and the protective aspects of this program and some incidental common utility in biological defence.

1994 – Present

In 1994, it was recognised that Australia's knowledge of toxins as warfare agents needed to be strengthened if appropriate advice on defensive measures was to be given to the Australian Defence Force and in support of the country's arms control objectives. Consequently, the Government gave approval to commence a modest program of Research into defence against toxins as warfare agents.

It was also recognised that the Government needed advice on defence against biological weapons if it was to pursue its aims of strengthening the Biological Weapons Convention. Consequently, the policy of maintaining only a watching brief on BW defence research was modified to allow research in BW defence that did not involve pathogenic reproducing organisms. Such activities as epidemiological studies, computer simulations and studies of the detection of toxins could then be undertaken.

In 1998, government approval was given for DSTO to undertake biological defence work with reproducing organisms up to Risk Group 3, with interdepartmental oversight of all such activities. This research allows Australia to play a larger part in those TTCP Panels that deal with BW defence research and obtain access to more information held by our cooperative partners. Australia still maintains its active program into researching protective aspects of defence against chemical agents and has expanded the scope to include utility defence against biological weapons. (eg incorporation of antibacterials in carbon adsorbents)

Declaration of vaccine production facilities

CSL is the only manufacturer licensed by the Australian Government pursuant to the *Therapeutic Goods Act 1989* to produce vaccines for the protection of humans included on the Australian Register of Therapeutic Goods (ARTG). The licence requires the manufacturer to comply with principles of Good Manufacturing Practice.

1. Name of facility:

CSL Limited

2. Location (mailing address):

45 Poplar Road
Parkville Victoria 3052
Australia

3. General description of the types of diseases covered:

Vaccine products must be entered in the Australian Register of Therapeutic Goods prior to supply of the products for human use. Registered products manufactured by CSL Limited are:

Diphtheria Vaccine
Diphtheria & Tetanus Vaccine
Influenza Vaccine
Plague Vaccine
Q fever Vaccine
Tetanus Toxoid Vaccine
Triple Antigen (Diphtheria, Tetanus, Pertussis)
Cholera Vaccine
Typhoid Vaccine
*Malarial Vaccine

* CSL manufactures the Malarial Vaccine for another sponsor, for export to Papua New Guinea only.

Note that Section 3, General Description of the Types of Diseases Covered, CSL Limited sponsor the following vaccines according to the Australian Register of Therapeutic Goods (ARTG):

Cholera Vaccine
Diphtheria and Tetanus Vaccine

Declaration of vaccine production facilities

Diphtheria Vaccine
Influenza Vaccine
Meningococcal Vaccine
Tetanus Toxoid Vaccine
Triple Antigen (Diphtheria, Tetanus, Pertussis)
Diphtheria, Tetanus, Pertussis and Hepatitis B Vaccine
Typhoid Vaccine
Q Fever Vaccine
Plague Vaccine
Yellow Fever Vaccine
Rotavirus Vaccine
Human Papilloma Virus Vaccine
Japanese Encephalitis Vaccine
Rabies Vaccine

There are some other manufacturers in Australia with GMP licences to produce biological goods – this category includes, but is not limited to, vaccines. These facilities are listed in the TGA document located at: www.tga.gov.au/manuf/licmanuf.pdf “Australian Manufacturers Licensed to Manufacture Therapeutic Goods” and are categorised as manufacturers of “Plasma and other biological products of human or animal origin Supply Units.” None of these manufacturers are listed on the ARTG as sponsors of vaccines (i.e. responsible for the commercial supply). CSL may use one or more of such GMP-licensed manufacturers to supply components of its vaccines.